Tetrahydropyridazines, compositions containing them and uses thereof
Tetrahydropyridazine compounds provide a CB1 receptor inhibition solution for metabolic disorders, effectively reducing food intake and body weight while avoiding neuropsychiatric side effects, addressing the limitations of existing CB1 receptor inhibitors.
Patent Information
- Application Number
- JP2024535980
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-12-17
- Filing Date
- 2022-12-16
- Publication Date
- 2024-12-05
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for alternative compounds that target the cannabinoid CB1 receptor to treat metabolic disorders without causing neuropsychiatric side effects, as seen with rimonabant.
Development of tetrahydropyridazine compounds and their pharmaceutically acceptable salts, which can inhibit the CB1 receptor to treat metabolic disorders such as obesity and associated conditions, while minimizing CNS-related side effects.
The tetrahydropyridazine compounds effectively reduce food intake, body weight, reverse insulin resistance, and improve metabolic parameters without significant CNS side effects, offering a safer treatment option for metabolic disorders.
Smart Images

Figure 2024545244000001_ABST
Abstract
Description
[Technical field]
[0001] Related Applications This application claims priority under applicable law to U.S. Provisional Application No. 63 / 265,583, filed December 17, 2021, the contents of which are incorporated herein by reference in their entirety for all purposes.
[0002] TECHNICAL FIELD This disclosure relates generally to compounds, particularly tetrahydropyridazine compounds, pharmaceutical compositions containing them, and their uses and methods of use in the treatment and prevention of diseases and disorders. [Background technology]
[0003] Cannabinoid CB 1 It is generally known that receptor activation increases appetite, increases lipid biosynthesis and storage, inhibits the action of insulin and leptin, and promotes inflammation and fibrosis. Therefore, research has been conducted to identify the role of CB12A1 and CB22A1 for the potential treatment of obesity and its associated metabolic disorders, called metabolic syndrome. 1 The focus was on developing receptor inhibitors. Rimonabant was shown to be effective in treating metabolic syndrome but caused neuropsychiatric (i.e., CNS-related) side effects that led to its removal from the market.
[0004] CB for the treatment or prevention of disorders related thereto 1 There remains a need for the development of alternative compounds that target the receptor. Summary of the Invention
[0005] According to one aspect, the present technology relates to compounds and their tautomers and / or pharma-ceutically acceptable salts, pharmaceutical compositions thereof, uses thereof, and therapeutic methods including administration thereof. More specifically, the following embodiments are provided:
[0006] Embodiment 1. Compound of Formula I [ka] (In the formula, R 1 is independently selected at each occurrence from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, halogen, cyano, nitro, hydroxy, optionally substituted alkoxy, amino, optionally substituted alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carboxyl, acyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted phosphonyl, optionally substituted phosphinyl, optionally substituted boronate, optionally substituted silyl, and imino; R 2 and R 3 are each independently selected from optionally substituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups; R 4 But -C(O)R 5 , -S(O) 2 R 5 , -C(=NR 6 )R 5 , and -C(=NR 6 )NHC(O)R 5 is selected from R 5 is selected from optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R 6 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R 6 But R5 and together with their adjacent atoms form an optionally substituted heterocycloalkyl or heteroaryl; X 1 But, SO 2 and C=O; a is 0, 1, 2, 3, 4, or 5; or an isomer and / or tautomer thereof, or a pharma- ceutically acceptable salt thereof. Embodiment 2. The compound is of formula I(a) [ka] (In the formula, R 1 ~R 4 , X 1 and a is as defined in embodiment 1. Embodiment 3. The compound is of formula I(b) [ka] (In the formula, R 1 ~R 4 , X 1 and a is as defined in embodiment 1. Embodiment 4.R 4 But -C(O)R 5 , -C(=NR 6 )R 5 , or -C(=NR 6 )NHC(O)R 5 The compound of any one of embodiments 1-3, wherein Embodiment 5.R 4 But -C(=NR 6 )NHC(O)R 5 The compound of embodiment 4, wherein Embodiment 6.R 5 , optionally replaced by C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-6 Alkylamino, or diC 1-6The compound of any one of embodiments 1-5, which is alkylamino. Embodiment 7.R 5 But, C 1-6 The compound of embodiment 6, wherein the alkyl is methyl. Embodiment 8.R 5 The compound of any one of embodiments 1-5, wherein is optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl. Embodiment 9.R 6 The compound of any one of embodiments 1-8, wherein is H. Embodiment 10.R 6 But R 5 and together with their adjacent atoms form an optionally substituted heterocycloalkyl or heteroaryl. Embodiment 11.X 1 But, SO 2 The compound of any one of embodiments 1-10, wherein In the embodiment 12.a, R 1 The compound of any one of embodiments 1-11, wherein is halogen. Embodiment 13.R 1 The compound of embodiment 12, wherein is Cl. Embodiment 14.R 3 , optionally replaced by C 2-6 The compound of any one of embodiments 1-13, which is an alkyl group. Embodiment 15.R 3 , optionally replaced by C 6 Aryl, C 5-6 Heteroaryl, or C 5-7 The compound of any one of embodiments 1-13, which is a heterocycloalkyl group. Embodiment 16.R 3 is of the formula [ka] (In the formula, R 7 may independently in each occurrence be halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 )=NR 10 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9 , N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 8 but independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 8 together with their neighboring atoms, C 4-10forming a heterocycloalkyl group, R 9 independently for each occurrence, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 10 but independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; The compound of embodiment 15, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 17.R 3 is of the formula [ka] (In the formula, X 2 , X 3 , X 4 , X 5 , and X 6 each independently represents N and CR 11 Selected from X 2 , X 3 , X 4 , X 5 , and X 6 At most three of them are N, R 11 may independently represent, at each occurrence, hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 )=NR 10 , S.O.2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9 , N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; c is 0, 1, 2, 3, 4, or 5; R 8 , R 9 , and R 10 is as defined in embodiment 16; The compound of embodiment 15, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 18.R 3 is of the formula [ka] (In the formula, X 7 But N and CR 11 is selected from X 8 , X9 , X 10 , X 11 , and X 12 each independently represents O, NR x , and C(R y ) 2 Selected from X 7 , X 8 , X 9 , X 10 , X 11 , and X 12 at most two of are or contain O or N, R 11 is as defined in embodiment 17, R x independently in each occurrence hydrogen, C(O)R 9 , C(O)N(R 8 ) 2 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R y may independently represent, at each occurrence, hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 )=NR 10 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9, N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R y together with their neighboring atoms, C 4-10 Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 8 , R 9 , and R 10 is as defined in embodiment 16; The compound of embodiment 15, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 19.R 11 or R y at least one occurrence of halogen (e.g., F or Cl) or halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 19. The compound of embodiment 17 or 18, wherein R is 1 or 2; Embodiment 20.R 11 or R y The compound of embodiment 17 or 18, wherein at each occurrence, is a hydrogen atom. Embodiment 21.R 2 , optionally replaced by C 2-6 The compound of any one of embodiments 1-20, which is an alkyl group. Embodiment 22.R 2 , optionally replaced by C 6 Aryl, C 5-6 Heteroaryl, or C 5-7 The compound of any one of embodiments 1-20, which is a heterocycloalkyl group. Embodiment 23.R 2 is of the formula [ka] (In the formula, R 12 may independently in each occurrence be halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 13 but independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 8 together with their neighboring atoms, C 4-10 forming a heterocycloalkyl group, R 14 independently for each occurrence, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 15 but independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; The compound of embodiment 22, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 24.R 2 is of the formula [ka] (In the formula, X 13 , X 14 , X15 , X 16 , and X 17 each independently represents N and CR 16 Selected from X 13 , X 14 , X 15 , X 16 , and X 17 At most three of them are N, R 16 may independently represent, at each occurrence, hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; c is 0, 1, 2, 3, 4, or 5; R 13 , R 14 , and R15 is as defined in embodiment 23; The compound of embodiment 22, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 25.R 2 is of the formula [ka] (In the formula, X 18 But N and CR 16 is selected from X 19 , X 20 , X 21 , X 22 , and X 23 each independently represents O, NR w , and C(R z ) 2 Selected from X 18 , X 19 , X 20 , X 21 , X 22 , and X 23 at most two of are or contain O or N, R 16 is as defined in embodiment 24, R w independently in each occurrence hydrogen, C(O)R 14 , C(O)N(R 13 ) 2 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R z may independently represent, at each occurrence, hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R z together with their neighboring atoms, C 4-10 Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 13 , R 14 , and R 15 is as defined in embodiment 23; The compound of embodiment 22, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted. Embodiment 26.R 16 or R z The compound according to embodiment 24 or 25, wherein at each occurrence, is a hydrogen atom. Embodiment 27.R 16 or R z at least one occurrence of halogen (e.g., F or Cl) or halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 26. The compound of embodiment 24 or 25, wherein R is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 25, 26, 27, 28, Embodiment 28. The compound is selected from the group consisting of: [ka] [ka] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof. Embodiment 29. The compound is selected from the group consisting of: [ka] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof. Embodiment 30. The compound is selected from the group consisting of: [ka] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof. Embodiment 31. A pharmaceutical composition comprising a compound according to any one of embodiments 1 to 30, together with a pharma- ceutically acceptable carrier, diluent, or excipient. Embodiment 32. Use of a compound as defined in any one of embodiments 1 to 30 or a pharmaceutical composition as defined in embodiment 31 for the treatment of an appetite-related disorder or one of its complications, a glucose regulation-related disorder or one of its complications, a fibrosis-related disorder or one of its complications, a metabolism-related disorder or one of its complications, a skin and hair growth and healing-related disorder, a gastrointestinal tract-related disorder, an obesity-related disorder or one of its complications, or a combination thereof. Embodiment 33. The use of embodiment 32, wherein one of said appetite-related disorders or complications thereof is selected from Prader-Willi syndrome (PWS), hypothalamic obesity, proopiomelanocortin (POMC) deficiency (including POMC obesity, heterozygous POMC deficiency obesity, POMC epigenetic disorders), leptin receptor (LepR) deficiency, Bardet-Biedl (BB) syndrome, and Alström syndrome. Embodiment 34. The use according to embodiment 32, wherein said glucose regulation-related disorder or one of its complications is selected from type I diabetes, type II diabetes, insulin resistance, prediabetes, pancreatic disease (by beta cell protection and / or increased insulin production), and associated nephropathy, neuropathy, and retinopathy. Embodiment 35. The use according to embodiment 32, wherein the fibrosis-related disorder or one of its complications is selected from progressive fibrosis associated with interstitial lung disease, idiopathic pulmonary fibrosis (IPF), Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), cirrhosis and other liver fibrosis disorders (such as non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis, primary biliary cholangitis), fibrotic kidney disease, skin fibrotic disorders (such as scleroderma), and chronic kidney disease. Embodiment 36. The use according to embodiment 32, wherein one of said metabolic-related disorders or complications thereof is selected from metabolic syndrome and hyperlipidemia (e.g., hypertriglyceridemia, hypertriglyceridemia in the setting of low HDL cholesterol, elevated LDL and / or total cholesterol and / or VLDL, and / or elevated apolipoprotein B, atherosclerotic cardiovascular disease, etc.). Embodiment 37. The use of embodiment 32, wherein one of said obesity-related disorders or complications thereof is selected from sleep apnea, snoring, asthma, pulmonary hypoventilation syndrome, dementia, cardiac disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, osteoarthritis, venous stasis ulcers, coronary artery disease, arteriosclerosis, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate, or gallbladder. Embodiment 38. The use according to embodiment 32, wherein the skin and hair growth and healing disorder is selected from alopecia (androgenetic alopecia and alopecia associated with metabolic syndrome), excessive scarring (scars and keloids), and scleroderma. Embodiment 39. The use according to embodiment 32, wherein the gastrointestinal tract-related disorder is selected from constipation, irritable bowel syndrome, and inflammatory bowel syndrome, including ulcerative colitis and Crohn's disease. Embodiment 40. A method for the treatment of a disorder selected from an appetite-related disorder or one of its complications, a glucose regulation-related disorder or one of its complications, a fibrosis-related disorder or one of its complications, a metabolism-related disorder or one of its complications, a skin and hair growth and healing-related disorder, a gastrointestinal tract-related disorder, an obesity-related disorder or one of its complications, or a combination thereof, comprising administering to a subject in need thereof a compound as defined in any one of embodiments 1 to 30 or a pharmaceutical composition as defined in embodiment 31. Embodiment 41. The method of embodiment 40, wherein the appetite-related disorder or complication thereof is selected from Prader-Willi syndrome (PWS), hypothalamic obesity, proopiomelanocortin (POMC) deficiency (including POMC obesity, heterozygous POMC deficiency obesity, POMC epigenetic disorders), leptin receptor (LepR) deficiency, Bardet-Biedl (BB) syndrome, and Alström syndrome. Embodiment 42. The method of embodiment 40, wherein said glucose regulation-related disorder or complication thereof is selected from type I diabetes, type II diabetes, insulin resistance, prediabetes, pancreatic disease (by beta cell protection and / or increased insulin production), and associated nephropathy, neuropathy, and retinopathy. Embodiment 43. The method of embodiment 40, wherein the fibrosis-related disorder or complication thereof is selected from progressive fibrosis associated with interstitial lung disease, idiopathic pulmonary fibrosis (IPF), Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), cirrhosis and other liver fibrosis disorders (such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, primary biliary cholangitis), fibrotic kidney disease, skin fibrotic disorders (such as scleroderma), and chronic kidney disease. Embodiment 44. The method of embodiment 40, wherein said metabolic-related disorder or complication thereof is selected from metabolic syndrome and hyperlipidemia (e.g., hypertriglyceridemia, hypertriglyceridemia in the setting of low HDL cholesterol, elevated LDL and / or total cholesterol and / or VLDL, and / or elevated apolipoprotein B, atherosclerotic cardiovascular disease, etc.). Embodiment 45. The method of embodiment 40, wherein the obesity-related disorder or complication thereof is selected from sleep apnea, snoring, obesity asthma, pulmonary hypoventilation syndrome, dementia, cardiac disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, osteoarthritis, venous stasis ulcers, coronary artery disease, arteriosclerosis, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate, or gallbladder. Embodiment 46. The method of embodiment 40, wherein the skin and hair growth and healing disorder is selected from alopecia (androgenetic alopecia and alopecia associated with metabolic syndrome), excessive scarring (scars and keloids), and scleroderma. Embodiment 47. The method of embodiment 40, wherein the gastrointestinal tract-related disorder is selected from constipation, irritable bowel syndrome, and inflammatory bowel syndrome, including ulcerative colitis and Crohn's disease. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] All technical terms and expressions used herein have the same definition as commonly understood by those skilled in the art to which this technology pertains.Nevertheless, the definitions of some terms and expressions used are provided below.If the definitions of terms in the publications, patents, and patent applications incorporated herein by reference are contrary to the definitions set forth herein, the definitions in this specification shall prevail.The section headings used herein are for organizational purposes only and should not be interpreted as limiting the disclosed subject matter.
[0008] The chemical structures described herein are drawn according to conventional standards. Also, when an atom, such as a drawn carbon atom, appears to contain incomplete valences, the valences are assumed to be satisfied by one or more hydrogen atoms, although not necessarily explicitly drawn. The hydrogen atoms should be assumed to be part of the compound.
[0009] The terminology used herein is intended to describe only certain embodiments and is not intended to be limiting. The singular forms "a," "an," and "the" include the plural unless the context clearly dictates otherwise. Thus, for example, a reference to a composition containing a compound also contemplates a mixture of two or more compounds. It should also be noted that the term "or" is generally used in its sense including "and / or" unless the context clearly dictates otherwise. Furthermore, when the terms "including," "includes," "having," "has," "with," or variations thereof are used in either the detailed description and / or claims, such terms are intended to be inclusive in a manner similar to the term "comprising."
[0010] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" may mean within one or more standard deviations, according to the practice in the art. Alternatively, "about" may mean within a range of up to 20%, preferably up to 10%, more preferably up to 5%, and even more preferably up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term may mean within 10-fold, preferably within 5-fold, and more preferably within 2-fold of a value. When a particular value is described in the present application and claims, the term "about" should be assumed to mean within an acceptable error range for the particular value, unless otherwise specified.
[0011] As used herein, the terms "compounds", "compounds described herein", "compounds of the present application", "tetrahydropyridazine", "tetrahydropyridazine compounds", and equivalent expressions refer to compounds described in the present application, such as those encompassed by structural formulas I, I(a), and I(b), optionally with reference to any of the applicable embodiments, and also include exemplary compounds, such as compounds 1-8, compounds 1A-8A, and compounds 1B-8B, their pharma- ceutical acceptable salts and tautomers, and, where applicable, their solvates, esters, and prodrugs. Where zwitterionic form is possible, the compounds may be depicted as their neutral form for practical purposes, but it is understood that the compounds also include their zwitterionic form. The embodiments herein may also exclude one or more of the compounds. The compounds may be identified by either their chemical structure or their chemical name. In the event of a conflict between the chemical structure and the chemical name, the chemical structure shall prevail.
[0012] Unless otherwise specified, structures depicted herein are also meant to include all isomeric (e.g., enantiomers, diastereomers, tautomers, and geometric (or conformational)) forms of the structure, where applicable, e.g., R and S configurations of each asymmetric center. Thus, single stereochemical isomers as well as enantiomeric, diastereomeric, tautomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of this specification. The present compounds also encompass all possible tautomers of the depicted compounds, if present, unless otherwise specified. The term also includes isotopically labeled compounds where one or more atoms have an atomic mass different from the atomic mass most abundantly found in nature. Examples of isotopes that may be incorporated into the present compounds include, but are not limited to, 2 H(D), 3 H(T), 11 C. 13 C. 14 C. 15 N, 18 O. 17O, any one of the isotopes of sulfur, etc. Compounds can also exist in unsolvated forms as well as solvated forms, including hydrated forms. Compounds can exist in multiple crystalline or non-crystalline forms. In general, all physical forms are equivalent for the use contemplated herein and are intended to be within the scope of the present invention.
[0013] When a particular enantiomer is preferred, in some embodiments it may be provided substantially free of the corresponding enantiomer, or it may be enantiomerically enriched. "Enantiomerically enriched" means that the compound is composed of a significantly higher proportion of one enantiomer. In certain embodiments, the compound is composed of at least about 90% by weight of the preferred enantiomer. In other embodiments, the compound is composed of at least about 95%, 98%, or 99% by weight of the preferred enantiomer. The preferred enantiomer may be isolated from a racemic mixture by any method known to those skilled in the art, including high pressure liquid chromatography (HPLC) or supercritical fluid chromatography (SFC) on a chiral support, or by the formation and crystallization of a chiral salt, or may be prepared by asymmetric synthesis.
[0014] The expression "pharmaceutically acceptable salt" refers to a salt of the compound of the present invention that is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, etc., within the scope of sound medical judgment, and is compatible with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, SM Berge, et al. describes pharmaceutically acceptable salts in detail in J.Pharmaceutical Sciences, 66:1-19 (1977). Salts can be prepared in situ during the final isolation and purification of the compound of the present invention, or can be prepared separately by reacting the free base function of the compound with a suitable organic or inorganic acid (acid addition salt), or by reacting the acidic function of the compound with a suitable organic or inorganic base (base addition salt).
[0015] The term "solvate" refers to a physical association of one of the compounds with one or more solvent molecules, including water and non-aqueous solvent molecules. This physical association may include hydrogen bonding. In certain instances, a solvate can be isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. The term "solvate" encompasses both solution-phase solvates and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, hemihydrates, ethanolates, hemiethanolates, n-propanolates, iso-propanolates, 1-butanolates, 2-butanolates, and solvates of other physiologically acceptable solvents, such as Class 3 solvents as described in International Conference on Harmonization (ICH), Guide for Industry, Q3C Impurities: Residual Solvents (1997). Thus, the compounds described herein also include each of their solvates and mixtures thereof.
[0016] As used herein, the expression "pharmaceutical acceptable ester" refers to an ester of a compound formed by the process herein, including those that hydrolyze in vivo and decompose easily in the human body to leave the parent compound or its salt. Suitable ester groups include, for example, those derived from pharmaceutical acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic, and alkanedioic acids, each alkyl or alkenyl moiety advantageously having 6 or fewer carbon atoms. Examples of specific esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates, and ethylsuccinates of hydroxyl groups, and alkyl esters of acidic groups. Other ester groups include sulfonates or sulfates.
[0017] As used herein, the expression "pharmaceutically acceptable salts" refers to prodrugs of compounds formed by the processes herein that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with no undue toxicity, irritation, allergic response, and the like, and that are compatible with a reasonable benefit / risk ratio and are effective for their intended use. As used herein, the term "prodrug" means a compound that is convertible in vivo by metabolic means (e.g., hydrolysis) to obtain any compound depicted by the formulas of the present description.
[0018] Unless otherwise noted, abbreviations may be used throughout this application and are intended to have the meanings commonly understood by those of skill in the art. Examples of such abbreviations include Me (methyl), Et (ethyl), Pr (propyl), i-Pr (isopropyl), Bu (butyl), t-Bu (tert-butyl), i-Bu (iso-butyl), s-Bu (sec-butyl), c-Bu (cyclobutyl), Ph (phenyl), Bn (benzyl), Bz (benzoyl), CBz or Cbz or Z (carbobenzyloxy), Boc or BOC (tert-butoxycarbonyl), and Su or Suc (succinimide).
[0019] The number of carbon atoms in a hydrocarbon substituent is indicated by the prefix "C x -C y " or "C x - y " where x is the minimum number of carbon atoms in the substituent and y is the maximum number of carbon atoms in the substituent. However, the prefix "C x -C y " or "C x - y When " is associated with a group that by definition incorporates one or more heteroatoms (e.g., heterocycloalkyl, heteroaryl, etc.), x and y define the minimum and maximum number of atoms in the period, respectively, including carbon atoms and heteroatoms.
[0020] The term "heteroatom" includes atoms other than carbon and hydrogen, such as, but not limited to, nitrogen, oxygen, or sulfur, including any oxidized form of nitrogen or sulfur, substituted forms of nitrogen, and any quaternized form of a basic nitrogen.
[0021] As used herein, the term "alkyl" refers to a saturated, straight or branched chain hydrocarbon radical, typically containing from 1 to 20 carbon atoms. For example, "C 1 - 8 Alkyl" contains 1 to 8 carbon atoms. Examples of alkyl radicals include, but are not limited to, methyl, ethyl, propyl, isopropyl, n-butyl, tert-butyl, neopentyl, n-hexyl, heptyl, octyl radicals, and the like.
[0022] As used herein, the term "alkenyl" refers to a straight or branched chain hydrocarbon radical containing one or more double bonds and typically 2 to 20 carbon atoms. For example, "C 2 - 8 Alkenyl" contains 2 to 8 carbon atoms. Alkenyl groups include, but are not limited to, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, heptenyl, octenyl, and the like.
[0023] As used herein, the term "alkynyl" refers to a straight or branched chain hydrocarbon radical containing one or more triple bonds and typically 2 to 20 carbon atoms. For example, "C 2 - 8 Alkynyl" contains 2 to 8 carbon atoms. Representative alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 1-butynyl, heptynyl, octynyl, and the like.
[0024] The terms "cycloalkyl," "alicyclic," "carbocyclic," and equivalent expressions refer to groups containing saturated or partially unsaturated (non-aromatic) carbocyclic rings in monocyclic or polycyclic ring systems, including spiro (sharing one atom), fused (sharing at least one bond), or bridged (sharing two or more bonds) carbocyclic ring systems having from 3 to 15 ring members. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopenten-1-yl, cyclopenten-2-yl, cyclopenten-3-yl, cyclohexyl, cyclohexen-1-yl, cyclohexen-2-yl, cyclohexen-3-yl, cycloheptyl, bicyclo[4,3,0]nonanyl, norbornyl, and the like. The term cycloalkyl includes both unsubstituted and substituted cycloalkyl groups. The term "cycloalkyl" includes both unsubstituted and substituted cycloalkyl groups. 3 - n "Cycloalkyl" refers to cycloalkyl groups having from 3 to the indicated "n" number of carbon atoms in their ring structure. Unless the number of carbons is otherwise specified, as used herein, "lower cycloalkyl" groups have at least 3 and no more than 8 carbon atoms in their ring structure.
[0025] As used herein, the terms "heterocycloalkyl", "heterocyclyl" and the like are used interchangeably and refer to a chemically stable 3-7 membered monocyclic or 7-10 membered bicyclic heterocycloalkyl moiety that is either saturated or partially unsaturated as defined above and has, in addition to carbon atoms, one or more, preferably 1-4 heteroatoms. As an example, in a saturated or partially unsaturated ring having 1-3 heteroatoms selected from oxygen, sulfur, or nitrogen, the nitrogen may be N (as in 3,4-dihydro-2H-pyrrolyl), ΝΗ (as in pyrrolidinyl), or NR (as in N-substituted pyrrolidinyl). A heterocycloalkyl can be attached to its pendant group at any heteroatom or carbon atom that results in a chemically stable structure, and any of the ring atoms can be optionally substituted. Examples of heterocycloalkyl groups include, but are not limited to, 1,3-dioxolanyl, pyrrolidinyl, pyrrolidonyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, tetrahydrofuranyl, tetrahydropyranyl, tetrahydrothiopyranyl, tetrahydrodithienyl, tetrahydrothienyl, thiomorpholino, thioxanyl, azetidinyl, oxetanyl, thietanyl, homopyranyl, cyclopyranyl, cyclopentaaryl ... Examples of the aryl group include peridinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, 3-azabicyclo[3,1,0]hexanyl, 3-azabicyclo[4,1,0]heptanyl, quinolidinyl, quinuclidinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and decahydroquinolinyl.Heterocycloalkyl groups also include groups in which the heterocycloalkyl ring is fused to one or more aryl, heteroaryl, or alicyclic rings, such as indolinyl, 3H-indolyl, chromanyl, chromenyl, phenanthridinyl, 2-azabicyclo[2.2.1]heptanyl, octahydroindolyl, or tetrahydroquinolinyl, when the radical or point of attachment is on the heterocycloalkyl ring. Heterocycloalkyl groups can be monocyclic or bicyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted by a heterocycloalkyl, where the alkyl and heterocyclyl portions are independently optionally substituted. For example, the term "C. 3 - n "Heterocycloalkyl" refers to a heterocycloalkyl group having from 3 to the indicated "n" number of atoms in the ring structure, which includes carbon atoms and heteroatoms.
[0026] As used herein, the term "partially unsaturated" refers to a ring moiety that contains at least one double or triple bond between ring atoms, but is not aromatic. The term "partially unsaturated" is intended to encompass rings with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties as defined herein.
[0027] The term "aryl" used alone or as part of a larger moiety such as "aralkyl", "aralkoxy", "aryloxy", or "aryloxyalkyl" refers to an aromatic group having 4n+2 conjugated π (pi) electrons, where n is an integer from 1 to 3 in a monocyclic moiety or in a bicyclic or tricyclic fused ring system having a total of 6 to 15 ring members, at least one ring in the system is aromatic, and each ring in the system contains 3 to 7 ring members. The term "aryl" may be used interchangeably with the expression "aryl ring". In certain embodiments herein, "aryl" refers to an aromatic ring or ring system, such as, but not limited to, phenyl, biphenyl, naphthyl, azulenyl, anthracyl, etc., which may bear one or more substituents. The term "aralkyl" or "arylalkyl" refers to an alkyl residue attached to an aryl ring. Examples of aralkyls include, but are not limited to, benzyl, phenethyl, etc. Also included within the scope of the term "aryl" as used herein are groups in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, indenyl, phthalimidyl, naphthymidyl, fluorenyl, phenanthridinyl, or tetrahydronaphthyl. 6 - n "Aryl" refers to an aryl group having 6 to the indicated "n" number of atoms in the ring structure.
[0028] The term "heteroaryl", e.g., "heteroaralkyl" or "heteroaralkoxy", used alone or as part of a larger moiety, refers to an aromatic group having 4n+2 conjugated π (pi) electrons, where n is an integer from 1 to 3 (e.g., having 5 to 18 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 pi electrons shared in the cyclic array), and having 1 to 5 heteroatoms in addition to the carbon atoms. The term "heteroatom" is as defined above. A heteroaryl can be a single ring, or two or more fused rings. The term "heteroaryl", as used herein, also includes groups in which a heteroaromatic ring is fused to one or more aryl, cycloalkyl, or heterocycloalkyl rings. Non-limiting examples of heteroaryl groups include thienyl, furanyl (furyl), pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, 3H-indolyl, isoindolyl, indolizinyl, benzothienyl (benzothiophenyl), benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, benzotriazolyl, pyrrolopyridinyl (e.g., pyrrolo[3,2-b]pyridinyl or pyrrolo[3,2-c]pyridinyl). ]pyridinyl), pyrazolopyridinyl (e.g., pyrazolo[1,5-a]pyridinyl), furopyridinyl, purinyl, imidazopyrazinyl (e.g., imidazo[4,5-b]pyrazinyl), quinolyl (quinolinyl), isoquinolyl (isoquinolinyl), quinolonyl, isoquinolonyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, naphthyridinyl, as well as pteridinylcarbazolyl, acridinyl, phenanthridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one. Heteroaryl groups can be monocyclic or bicyclic. Heteroaryl groups include optionally substituted rings.The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl, where the alkyl and heteroaryl portions independently are optionally substituted. Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl, and the like. For example, the term "C. 5 - n "Heteroaryl" refers to heteroaryl groups having from 5 to the indicated "n" number of atoms in the ring structure, including carbon atoms and heteroatoms.
[0029] The terms "halogen" or "halo" refer to a halogen atom, that is, a fluorine, chlorine, bromine, or iodine atom, preferably fluorine or chlorine.
[0030] As described herein, the compounds herein may include "optionally substituted" moieties. In general, the term "substituted" means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at any or each substitutable position of the group, and if more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be the same or different at each position. The combination of substituents contemplated herein is preferably one that results in the formation of a chemically stable or chemically feasible compound. As used herein, the term "chemically stable" refers to a compound that is substantially unchanged when subjected to conditions to enable their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0031] Examples of substituents include, but are not limited to, halogens (F, CI, Br, I), OH, CO 2 H, alkoxy, oxo, thiooxo, NO 2 , C.N., C.F. 3 , CHF 2 , N.H. 2, NHalkyl, NHalkenyl, NHalkynyl, NHcycloalkyl, NHaryl, NHheteroaryl, NHheterocycloalkyl, dialkylamino, diarylamino, diheteroarylamino, O-alkyl, O-alkenyl, O-alkynyl, O-cycloalkyl, O-aryl, O-heteroaryl, O-haloalkyl, O-heterocycloalkyl, C(O)alkyl, C(O)alkenyl, C(O)alkynyl, C(O)cycloalkyl, C(O)aryl, C(O)heteroaryl, C(O)heterocycloalkyl, CO 2 Alkyl, CO 2 Alkenyl, CO 2 Alkynyl, CO 2 Cycloalkyl, CO 2 Aryl, CO 2 Heteroaryl, CO 2 Heterocycloalkyl, OC(O)alkyl, OC(O)alkenyl, OC(O)alkynyl, OC(O)cycloalkyl, OC(O)aryl, OC(O)heteroaryl, OC(O)heterocycloalkyl, C(O)NH 2 , C(O)NH alkyl, C(O)NH alkenyl, C(O)NH alkynyl, C(O)NH cycloalkyl, C(O)NH aryl, C(O)NH heteroaryl, C(O)NH heterocycloalkyl, OCO 2 Alkyl, OCO 2 Alkenyl, OCO 2 Alkynyl, OCO 2 Cycloalkyl, OCO 2 Aryl, OCO 2 Heteroaryl, OCO 2 Heterocycloalkyl, OC(O)NH 2 , OC(O)NH alkyl, OC(O)NH alkenyl, OC(O)NH alkynyl, OC(O)NH cycloalkyl, OC(O)NH aryl, OC(O)NH heteroaryl, OC(O)NH heterocycloalkyl, NHC(O) alkyl, NHC(O) alkenyl, NHC(O) alkynyl, NHC(O) cycloalkyl, NHC(O) aryl, NHC(O) heteroaryl, NHC(O) heterocycloalkyl, NHCO 2 Alkyl, NHCO 2Alkenyl, NHCO 2 Alkynyl, NHCO 2 Cycloalkyl, NHCO 2 Aryl, NHCO 2 Heteroaryl, NHCO 2 Heterocycloalkyl, NHC(O)NH 2 , NHC(O)NH alkyl, NHC(O)NH alkenyl, NHC(O)NH alkenyl, NHC(O)NH cycloalkyl, NHC(O)NH aryl, NHC(O)NH heteroaryl, NHC(O)NH heterocycloalkyl, NHC(S)NH 2 , NHC(S)NH alkyl, NHC(S)NH alkenyl, NHC(S)NH alkynyl, NHC(S)NH cycloalkyl, NHC(S)NH aryl, NHC(S)NH heteroaryl, NHC(S)NH heterocycloalkyl, NHC(NH)NH 2 , NHC(NH)NH alkyl, NHC(NH)NH alkenyl, NHC(NH)NH alkenyl, NHC(NH)NH cycloalkyl, NHC(NH)NH aryl, NHC(NH)NH heteroaryl, NHC(NH)NH heterocycloalkyl, NHC(NH) alkyl, NHC(NH) alkenyl, NHC(NH) alkenyl, NHC(NH) cycloalkyl, NHC(NH) aryl, NHC(NH) heteroaryl, NHC(NH) heterocycloalkyl, C(NH)NH alkyl, C(NH)NH alkenyl, C(NH)NH alkynyl, C(NH)NH cycloalkyl, C(NH)NH aryl, C(NH)NH heteroaryl, C(NH)NH heterocycloalkyl, S(O) alkyl, S(O) alkenyl, S(O) alkynyl, S(O) cycloalkyl, S(O) aryl, S(O) 2 Alkyl, S(O) 2 Alkenyl, S(O) 2 Alkynyl, S(O) 2 Cycloalkyl, S(O) 2 Aryl, S(O)heteroaryl, S(O)heterocycloalkyl, SO 2 NH 2 , S.O. 2 NH alkyl, SO 2 NH Alkenyl, SO 2NH alkynyl, SO 2 NH Cycloalkyl, SO 2 NHaryl, SO 2 NH Heteroaryl, SO 2 NHHeterocycloalkyl, NHSO 2 Alkyl, NHSO 2 Alkenyl, NHSO 2 Alkynyl, NHSO 2 Cycloalkyl, NHSO 2 Aryl, NHSO 2 Heteroaryl, NHSO 2 Heterocycloalkyl, CH 2 NH 2 , C.H. 2 SO 2 CH 3 , alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, cycloalkyl, carbocyclic, heterocycloalkyl, polyalkoxyalkyl, polyalkoxy, methoxymethoxy, methoxyethoxy, SH, S-alkyl, S-alkenyl, S-alkynyl, S-cycloalkyl, S-aryl, S-heteroaryl, S-heterocycloalkyl, or methylthiomethyl. Each of these substituents can also be further substituted, where possible.
[0032] Thus, this document to the tetrahydropyridazine compounds defined herein and in the following paragraphs. When referring to a chemical moiety, the recitation of a list of chemical groups in any definition of a variable includes the definition of that variable as any single group or combination of the listed groups. Similarly, the recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof. Thus, the following embodiments exist alone or in combination, where applicable:
[0033] The compounds exhibit a tetrahydropyridazine core structure bonded to the defined substituents. Exemplary compounds as defined herein have the general formula I [ka] (In the formula, R 1 is independently selected at each occurrence from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, halogen, cyano, nitro, hydroxy, optionally substituted alkoxy, amino, optionally substituted alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carboxyl, acyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted phosphonyl, optionally substituted phosphinyl, optionally substituted boronate, optionally substituted silyl, and imino; R 2 and R 3 are each independently selected from optionally substituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups; R 4 is -C(O)R 5 , -S(O) 2 R 5 , -C(=NR 6 )R 5 , and -C(=NR 6 )NHC(O)R 5 is selected from R 5 is selected from optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R 6 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R 6 is R5 and together with their adjacent atoms form an optionally substituted heterocycloalkyl or heteroaryl; X 1 SO 2 and C=O; a is 0, 1, 2, 3, 4, or 5; or an isomer and / or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
[0034] In the above formula, the compounds may be in the form of specific isomers, e.g., those of formula I(a) [ka] (In the formula, R 1 ~R 4 , X 1 wherein a is as previously defined), or an isomer and / or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
[0035] In the above formula, the compound may be in different isomers, for example, isomers of formula I(b) [ka] (In the formula, R 1 ~R 4 , X 1 wherein a is as previously defined), or an isomer and / or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
[0036] In some examples of the above formula, R 4 is -C(O)R 5 , -C(=NR 6 )R 5 , or -C(=NR 6 )NHC(O)R 5 and preferably R 4 is -C(=NR 6 )NHC(O)R 5 It is.
[0037] R 5 is optionally replaced by C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy or optionally substituted C 1-6 Alkylamino or diC 1-6 may be defined as an alkylamino group, for example, R 5 is methyl, ethyl, propyl, etc. 1-6 It may be an alkyl group (eg, a methyl group).
[0038] R 5 may also be defined as an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, or an optionally substituted heteroaryl group.
[0039] In some compounds, R 6 is H. In other compounds, R 6 is R 5 and together with their adjacent atoms may form an optionally substituted heterocycloalkyl or heteroaryl.
[0040] In some cases, X 1 can be C=O. In other examples, X 1 SO 2 It is.
[0041] For example, in compounds of formula I, I(a), and I(b), R 1 is a halogen atom, for example, R 1 is a chlorine atom.
[0042] Some of the compounds of formula I, formula I(a), and formula I(b) may include an optionally substituted C 2-6 R is an alkyl group 3 In other compounds, R 3 is optionally replaced by C 6 Aryl, C 5-6 Heteroaryl, or C5-7 It may be a heterocycloalkyl group.
[0043] For example, R 3 is a functional group of the formula [ka] (In the formula, R 7 is independently in each occurrence a halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 )=NR 10 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9 , N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 8 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 8 together with their neighboring atoms, C 4-10 forming a heterocycloalkyl group, R 9 independently in each occurrence, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 10 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0044] Alternatively, R 3 is a functional group of the formula [ka] (In the formula, X 2 , X 3 , X 4 , X 5 , and X 6 each independently represents N and CR 11 Selected from X 2 , X 3 , X 4 , X 5 , and X 6At most three of them are N, R 11 is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 )=NR 10 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9 , N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; c is 0, 1, 2, 3, 4, or 5; R 8 , R 9 , and R 10 is as defined herein; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0045] On the other hand, R 3 Rather, it is a functional group of the formula [ka] (In the formula, X 7 N and CR 11 is selected from X 8 , X 9 , X 10 , X 11 , and X 12 each independently represents O, NR x , and C(R y ) 2 Selected from X 7 , X 8 , X 9 , X 10 , X 11 , and X 12 at most two of are or contain O or N; R x is independently in each occurrence hydrogen, C(O)R 9 , C(O)N(R 8 ) 2 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R y is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R10 )=NR 10 , S.O. 2 R 9 , S.O. 2 N(R 8 ) 2 , N(R 10 )C(O)R 9 , N(R 10 )SO 2 R 9 , N(R 10 )C(O)N(R 8 ) 2 , N(R 10 )SO 2 N(R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R y together with their neighboring atoms, C 4-10 Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 8 , R 9 , R 10 , and R 11 is as defined herein; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0046] In some instances, R 11 or R yis, in at least one occurrence, a halogen (e.g., F or Cl) or a halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 In another example, R 11 or R y is a hydrogen atom in each occurrence.
[0047] Some of the compounds of formula I, formula I(a), and formula I(b) may include an optionally substituted C 2-6 R is an alkyl group 2 In other compounds, R 2 is optionally replaced by C 6 Aryl, C 5-6 Heteroaryl, or C 5-7 It may be a heterocycloalkyl group.
[0048] For example, R 2 is a functional group of the formula [ka] (In the formula, R 12 is independently in each occurrence a halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 )2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 13 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 13 together with their neighboring atoms, C 4-10 forming a heterocycloalkyl group, R 14 independently in each occurrence, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 15 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0049] Alternatively, R 2 is a functional group of the formula [ka] (In the formula, X 13 , X 14 , X 15 , X 16 , and X 17 each independently represents N and CR 16 Selected from X 13 , X 14 , X 15 , X 16 , and X 17 At most three of them are N, R 16 is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; c is 0, 1, 2, 3, 4, or 5; R 13 , R 14 , and R 15 is as defined herein; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0050] Or, R 2 is a functional group of the formula [ka] (In the formula, X 18 N and CR 16 is selected from X 19 , X 20 , X 21 , X 22 , and X 23 each independently represents O, NR w , and C(R z ) 2 Selected from X 18 , X 19 , X 20 , X 21 , X 22 , and X 23 at most two of are or contain O or N; R w is independently in each occurrence hydrogen, C(O)R 14 , C(O)N(R 13 ) 2 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R z is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 )=NR 15 , S.O. 2 R 14 , S.O. 2 N(R 13 ) 2 , N(R 15 )C(O)R 14 , N(R 15 )SO 2 R 14 , N(R 15 )C(O)N(R 13 ) 2 , N(R 15 )SO 2 N(R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, OC 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R z together with their neighboring atoms, C 4-10Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 13 , R 14 , R 15 , and R 16 is as defined herein; The alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl groups are optionally further substituted.
[0051] In some instances, R 16 or R z is a hydrogen atom in each occurrence. 16 or R z is, in at least one occurrence, a halogen (e.g., F or Cl) or a halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 alkyl).
[0052] Non-limiting examples of compounds of formula I are: [ka] or its isomers and / or tautomers, or pharma- ceutically acceptable salts thereof.
[0053] Non-limiting examples of compounds of formula I(a) are: [ka] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.
[0054] Non-limiting examples of compounds of formula I(b) are: [ka] or a tautomer thereof, or a pharma- ceutically acceptable salt thereof.
[0055] These compounds may be prepared by conventional chemical synthesis, such as those described in the Examples section below. As can be appreciated by those skilled in the art, further methods of synthesizing the compounds of the formulae herein will be apparent to those skilled in the art. Additionally, the various synthetic steps may be performed in an alternative sequence or order to obtain the desired compounds.
[0056] The compounds defined herein can be formulated in pharmaceutical compositions for administration to a subject, where the compounds are typically mixed with at least one pharma- ceutically acceptable carrier, diluent, or excipient.
[0057] The phrase "pharmacologically acceptable carrier, diluent, or excipient" and equivalent phrases refer to a non-toxic carrier, diluent, or excipient that does not destroy the pharmacological activity of the compound with which it is formulated.
[0058] The compositions described herein may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, or via an implanted reservoir.As used herein, the term "parenteral" includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, and intralesional injection or infusion techniques.Other modes of administration also include intradermal or transdermal administration.
[0059] For example, the solid dosage form for oral administration includes capsules, tablets, pills and granules.In a preferred alternative, the composition is a solid dosage form comprising the compound as described herein and at least one binder as defined in the preceding paragraph, and the binder preferably comprises microcrystalline cellulose.
[0060] Pharmaceutically acceptable carriers, diluents, or excipients that may be used in the oral compositions of the present disclosure include, but are not limited to, binders, sweeteners, disintegrants, diluents, flavorings, coatings, preservatives, lubricants, and / or polymers. Examples of binders include cellulose-based substances such as microcrystalline cellulose and carboxymethylcellulose, and other binders such as gum acacia, gelatin, corn starch, gum tragacanth, sodium alginate, or polyethylene glycol (PEG). Examples of sweeteners include sucrose, lactose, glucose, aspartame, or saccharin. Disintegrants include corn starch, methylcellulose, polyvinylpyrrolidone, xanthan gum, bentonite, alginic acid, or agar. Examples of diluents include lactose, sorbitol, mannitol, dextrose, kaolin, cellulose, calcium carbonate, calcium silicate, or dicalcium phosphate. Flavoring agents include peppermint oil, oil of wintergreen, cherry, orange, or raspberry flavoring agents. Coating agents include polymers or copolymers of acrylic acid and / or methacrylic acid and / or their esters, waxes, fatty alcohols, zein, shellac, or gluten. Suitable preservatives include sodium benzoate, vitamin E, alpha-tocopherol, ascorbic acid, methylparaben, propylparaben, or sodium bisulfite. Suitable lubricants include magnesium stearate, stearic acid, sodium oleate, sodium chloride, or talc. Examples of excipients may further include a polymer selected from the group consisting of polyvinylpyrrolidone (PVP), polyvinylpyrrolidone-vinyl acetate copolymer (PVP-VA), hydroxypropyl methylcellulose (HPMC), hypromellose-acetate-succinate (HPMCAS), and mixtures thereof.
[0061] The composition may also be used as a filler in soft and hard filled capsules.The solid dosage forms of tablets, dragees, capsules, pills, and granules may be prepared with coatings and shells, such as enteric coatings and other coatings well known in pharmaceutical formulation technology.They may optionally contain emulsifying agents, and may optionally be of a composition that releases active ingredient only or preferentially in a certain part of the intestinal tract, in a delayed manner.Examples of embedding compositions that may be used include polymeric substances and waxes.The composition may also be in microencapsulated form with one or more of the above-mentioned excipients.
[0062] Liquid dosage forms for oral administration include, but are not limited to, pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.In addition to active compounds, liquid dosage forms can contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, and mixtures thereof.In addition to inert diluents, these oral compositions can also contain adjuvants, such as wetting agents, emulsifiers and suspending agents, surfactants, sweeteners, flavorings, and aromatics.
[0063] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations may also be sterile injectable solutions, suspensions, or emulsions in non-toxic parenterally acceptable diluents or solvents, for example, as a solution in 1,3-butanediol. Acceptable vehicles and solvents that may be used include water, Ringer's solution (USP), and isotonic sodium chloride solution. In addition, sterile fixed oils are conventionally used as solvents or suspending media. For this purpose, any non-irritating fixed oil may be used, including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.
[0064] The injectable preparations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
[0065] In order to prolong the effect of the compound provided, it is often desirable to delay the absorption of the compound from subcutaneous or intramuscular injection. This can be achieved by using a liquid suspension of crystalline or amorphous material with low water solubility. The absorption rate of the compound then depends on its dissolution rate, which in turn can depend on crystal size and crystalline form. Alternatively, the delayed absorption of parenterally administered compound forms is achieved by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending on the ratio of compound to polymer and the nature of the particular polymer used, the release rate of the compound can be controlled.
[0066] Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
[0067] The dosage forms for topical or transdermal administration of the compounds herein include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants, or patches. The active ingredient is mixed under sterile conditions with a pharma- ceutically acceptable carrier, and any necessary preservatives or buffers, if necessary. Ophthalmic preparations, ear drops, and eye drops are also contemplated within the scope of the present invention. In addition, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of the compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in a suitable medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by providing a rate-controlling membrane or by dispersing the compound in a polymer matrix or gel.
[0068] The pharma- ceutically acceptable compositions provided herein may also be administered by nasal aerosol or inhalation.Such compositions are prepared according to techniques well known in the art of pharmaceutical formulation and may be prepared as a solution in saline using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons, and / or other conventional solubilizing or dispersing agents.
[0069] The amount of compound that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the patient treated and the particular mode of administration.
[0070] As used herein, the term "effective amount" refers to an amount of a compound that induces a biological or medical response in a tissue, system, animal, or human that is desired, for example, by a researcher or clinician.Furthermore, the term "therapeutically effective amount" refers to any amount that results in the treatment, cure, prevention, or amelioration of a disease, disorder, or its symptoms, or a reduction in the rate of progression of a disease or disorder, compared to a corresponding subject that does not receive such amount.This term also includes amounts within that range that are effective for enhancing normal physiological function.
[0071] As used herein, the terms "treatment", "treat" and "treating" refer to reversing, alleviating, delaying the onset, or inhibiting the progression of a disease or disorder described herein, or one or more symptoms thereof. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and / or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have disappeared, for example, to prevent or delay their recurrence.
[0072] As used herein, the term "patient" or "subject" refers to an animal, such as a mammal. Thus, a subject may refer to, for example, a mouse, a rat, a dog, a cat, a horse, a cow, a pig, a guinea pig, a primate, including a human, etc. Preferably, the subject is a human.
[0073] This compound binds to the cannabinoid receptor CB 1The compounds are useful in the treatment of diseases and disorders in which inhibition of is indicated. Thus, contemplated herein are the use of the compounds for the treatment of diseases or disorders as defined herein, the use of the compounds in the manufacture of a medicament for the treatment of diseases or disorders as defined herein, the compounds as defined herein for use in the treatment of diseases or disorders, and methods for treating diseases or disorders as defined herein, comprising administering one of the compounds to a subject in need thereof. Such diseases and disorders may generally be associated with diabetes and metabolic disorders (e.g., metabolic syndrome). Preferably, the compounds inhibit CB1 activity in brain tissue. 1 While they do not or mainly do not interact with receptors, CB 1 The receptors are selectively targeted, thereby avoiding or reducing CNS-related side effects.
[0074] Effects of the compounds may include reduced food intake, reduced body weight, reversal of insulin and leptin resistance, reversal of hepatic steatosis (fatty liver), and improvement of dyslipidemia. Examples of diseases and disorders to be treated include obesity, diabetes mellitus (type I or type II), non-alcoholic and alcoholic fatty liver disease (risk factors for insulin resistance), comorbidities of obesity, comorbidities of diabetes, Prader-Willi syndrome (PWS), pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor (LepR) deficiency obesity, POMC heterozygous deficiency obesity, POMC epigenetic disorders, Bardet-Biedl (BB) syndrome, Alström syndrome, dyslipidemia predisposing to atherosclerotic heart disease, diabetic nephropathy, fibrosis and fibrotic diseases of the skin, liver, lungs, or kidneys such as idiopathic pulmonary fibrosis (IPF), progressive fibrotic interstitial lung disease, Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), liver cirrhosis, renal fibrosis, scleroderma, and gout. In addition, skin disorders include reducing scar formation (scar, keloid) and alopecia, especially those associated with male pattern baldness and metabolic syndrome.For example, obesity comorbidities are selected from metabolic syndrome, dementia, heart disease, dementia, heart disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, osteoarthritis, venous stasis ulcer, pulmonary hypoventilation syndrome, sleep apnea, snoring, obesity asthma, coronary artery disease, arteriosclerosis, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of liver, ovarian, cervical, uterine, breast, prostate, or gallbladder malignant tumors.In a preferred example, the disease or disorder includes diabetes (type I or type II), obesity, and nonalcoholic fatty liver disease (e.g., nonalcoholic steatohepatitis).Examples of diabetes (e.g., type I) comorbidities include diabetic nephropathy, chronic kidney disease, diabetic retinopathy, and peripheral and autonomic neuropathy.
[0075] The disease, disorder and condition to be treated, including the above, can be divided into various categories, while some conditions can coexist in a given subject.Examples of categories include appetite-related disorder and its complications, glucose regulation-related disorder and its complications, fibrosis-related disorder and its complications, metabolism-related disorder and its complications, skin and hair growth and healing-related disorder, gastrointestinal tract-related disorder, and obesity-related disorder and its complications.
[0076] Examples of appetite-related disorders and their complications include, but are not limited to, Prader-Willi syndrome (PWS), hypothalamic obesity, proopiomelanocortin (POMC) deficiency (including POMC obesity, heterozygous POMC deficiency obesity, and POMC epigenetic disorders), leptin receptor (LepR) deficiency, Bardet-Biedl (BB) syndrome, and Alström syndrome.
[0077] Examples of disorders related to glucose regulation and their complications include, but are not limited to, type I diabetes, type II diabetes, insulin resistance, prediabetes, pancreatic disease (by beta cell protection and / or increased insulin production), and associated nephropathy, neuropathy, and retinopathy.
[0078] Examples of fibrosis-related disorders or complications thereof include, but are not limited to, progressive fibrosis associated with interstitial lung disease, idiopathic pulmonary fibrosis (IPF), Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), cirrhosis and other liver fibrotic disorders (such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, primary biliary cholangitis), fibrotic kidney disease, skin fibrotic disorders (such as scleroderma), and chronic kidney disease.
[0079] Examples of metabolism-related disorders or their complications include, but are not limited to, metabolic syndrome and hyperlipidemia (e.g., hypertriglyceridemia, hypertriglyceridemia in the setting of low HDL cholesterol, elevated LDL and / or total cholesterol and / or VLDL, and / or elevated apolipoprotein B, atherosclerotic cardiovascular disease, etc.).
[0080] Examples of obesity-related disorders or their complications include, but are not limited to, sleep apnea, snoring, asthma, pulmonary hypoventilation syndrome, dementia, cardiac disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, osteoarthritis, venous stasis ulcers, coronary artery disease, arteriosclerosis, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate, or gallbladder.
[0081] Examples of skin and hair disorders include alopecia (androgenetic alopecia and alopecia associated with metabolic syndrome), excessive scarring (scars and keloids), and scleroderma, among others.
[0082] Examples of disorders related to the gastrointestinal tract include constipation, irritable bowel syndrome, and inflammatory bowel syndrome, including ulcerative colitis and Crohn's disease.
[0083] Other disorders may also benefit from the compounds, including muscle wasting disorders including muscular dystrophies (such as Duchenne muscular dystrophy (DMD)), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), spinal muscular atrophy, and others.
[0084] The solid compounds and compositions may also be used in methods for preventing or reversing the deposition of adipose tissue in a subject, which is expected to contribute to reducing the incidence or severity of obesity, which in turn will reduce the incidence or severity of associated comorbidities.
[0085] The present specification provides a method for treating a disorder (described herein) in a subject, the method comprising administering a compound or composition of the present specification to a subject identified as needing the same. Identifying those patients who need the above-mentioned disorder treatment is well within the ability and knowledge of those skilled in the art. Certain methods for identifying patients at risk of developing the above-mentioned disorders that can be treated by the subject method are understood in the medical arts, such as family history and the presence of risk factors related to the development of the disease state in the subject patient. A clinician in the art can easily identify such candidate patients, for example, by using clinical tests, physical examinations, medical / family history, and genetic determination.
[0086] The method of evaluating the effectiveness of treatment in a subject includes determining pre-treatment symptoms of the disorder by methods well known in the art, and then administering a therapeutically effective amount of a compound of the present invention to the subject. After an appropriate period (e.g., 1 week, 2 weeks, 1 month, 6 months) after administration of the compound, re-evaluate the symptoms of the disorder. Modulation (e.g., reduction) of the symptoms and / or biomarkers of the disorder indicates the effectiveness of the treatment. The symptoms and / or biomarkers of the disorder can be determined periodically throughout the treatment. For example, the symptoms and / or biomarkers of the disorder can be checked every few days, weeks, or months to evaluate the further effectiveness of the treatment. The reduction of the symptoms and / or biomarkers of the disorder indicates that the treatment is effective.
[0087] The pharmaceutical compositions provided herein are preferably adapted for oral administration. Such formulations may be administered with or without food. The compositions are formulated in unit dosage form for ease of administration and uniformity of dosage. As used herein, the expression "unit dosage form" refers to a physically separate pharmaceutical unit suitable for the patient to be treated. However, it will be understood that the total daily dosage of the solid dispersions and compositions of the present disclosure will be determined by the attending physician within the scope of sound medical judgment.
[0088] The amount of the composition that may be included in a single dosage form varies depending on the patient being treated (e.g., child vs. adult, etc.) and the particular compound included in the composition. The provided compositions may be formulated such that a total daily dose of, for example, 0.01-100 mg / kg body weight / day or 0.01-20 mg / kg body weight / day of the compound may be administered to a patient receiving these compositions. A single dose composition may contain such amounts, or the total daily dose may be divided into multiple dosage forms to be taken, for example, once, twice, or three times a day. For example, a single dose may contain 5-500 mg of active ingredient, or 20-200 mg. A treatment regimen may include administering to a patient a total amount of about 10 mg to about 1000 mg of the compound herein per day, either in a single dose or divided into multiple doses.
[0089] It will be understood that the total daily dose of compound is determined by the attending physician within the scope of sound medical judgment.For example, the specific dose or treatment regimen for any particular patient depends on various factors, including age, body weight, general health, sex, diet, administration time, excretion rate, drug combination, the judgment of the treating physician, and the severity of the symptoms related to disease or disorder.
[0090] Depending on the disease or disorder to be treated, additional therapeutic agents may also be present in the composition of the present disclosure or may be co-administered separately.Non-limiting examples of additional therapeutic agents that can be used in combination with the present solid dispersions and formulations include antidiabetic drugs, cholesterol-lowering drugs, anti-inflammatory agents, antibacterial agents, matrix metalloproteinase inhibitors, lipoxygenase inhibitors, cytokine antagonists, immunosuppressants, anticancer drugs, antiviral drugs, cytokines, growth factors, immunomodulators, prostaglandins, or anti-vascular hyperproliferation compounds.Treatment can also be complemented by other treatments or interventions, such as surgery, radiation therapy (e.g., gamma radiation, neutron radiation therapy, electron beam radiation therapy, proton therapy, brachytherapy, and whole body radioisotopes), biological response modifiers (e.g., interferons, interleukins, tumor necrosis factor (TNF)), and agents used to attenuate the adverse effects of the present compound or co-administered components.
[0091] The recitation of an embodiment for a variable herein includes that embodiment as any single embodiment or in combination with any other embodiment or portions thereof. The recitation of an embodiment herein includes that embodiment as any single embodiment or in combination with any other embodiment or portions thereof. EXAMPLES
[0092] The following non-limiting examples are illustrative embodiments and should not be construed as further limiting the scope of the invention, which will be better understood with reference to the accompanying drawings.
[0093] Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, concentrations, properties, stability, and the like used in the specification and claims should be understood in all cases to be modified by the term "about". At the very least, each numerical parameter should be interpreted in light of the number of reported significant digits and by applying ordinary rounding techniques. Thus, unless indicated to the contrary, the numerical parameters set forth in the specification and appended claims are approximations that may vary depending on the properties sought to be obtained. Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the embodiments are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. However, any numerical value inherently contains certain errors resulting from variables such as experiments, testing measurements, statistical analyses, and the like.
[0094] [Example 1 - Synthesis of intermediate I-1] Scheme 1 shows an example of a synthesis for preparing intermediate I-1 shown below. [ka]
[0095] Step 1: Synthesis of Compound A-2 To a mixture of sodium hydride (3.5 g, 86.7 mmol, 60% purity, 1 equiv.) in dimethyl sulfoxide (45 mL) was added a solution of 1-(4-chlorophenyl)-2-phenyl-ethanone A-1 (20 g, 86.7 mmol, 1 equiv.) in dimethyl sulfoxide (111 mL). Then, a solution of methyl 2-bromoacetate (13.3 g, 86.7 mmol, 8.2 mL, 1 equiv.) in toluene (68 mL) was added and the mixture was stirred at 25° C. for 16 h. The mixture was poured into hydrochloric acid (1 M, 200 mL) and extracted with 600 mL of ethyl acetate (3×200 mL). The organic phase was then washed with brine (500 mL), dried over anhydrous sodium sulfate, and concentrated to give a residue. The residue was triturated with petroleum ether (100 mL) to give the product methyl 4-(4-chlorophenyl)-4-oxo-3-phenyl-butanoate A-2 (17.0 g) as a pale yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=8.08-7.99(m,2H),7.57-7.51(m,2H),7.36-7.27(m,4H),7.24-7.18(m,1H),5.25(m,1H),3.57(s,3H),3.23(m,1H),2.74(m,1H).
[0096] Step 2: Synthesis of Compound A-3 To a solution of methyl 4-(4-chlorophenyl)-4-oxo-3-phenyl-butanoate A-2 (17 g, 56.2 mmol, 1 equiv.) in ethanol (35 mL) was added a solution of sodium hydroxide (22.5 g, 561.5 mmol, 10 equiv.) in water (35 mL). The mixture was then stirred at 25° C. for 2 h. After evaporation of the ethanol, the residue was diluted with water (200 mL) and washed with ethyl acetate (3×50 mL). The aqueous layer was then acidified by 6N hydrochloric acid (50 mL) and extracted with ethyl acetate (3×200 mL). After drying over sodium sulfate and evaporation of the solvent, the product 4-(4-chlorophenyl)-4-oxo-3-phenyl-butanoic acid A-3 (13 g) was obtained as a pale yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=12.31(br s,1H),8.03(d,J=8.8Hz,2H),7.53(d,J=8.8Hz,2H),7.35-7.26(m,4H),7.23-7.17(m,1H),5.19(m,1H),3.16(m,1H),2.63(m,1H).
[0097] Step 3: Synthesis of compound A-4 To a solution of 4-(4-chlorophenyl)-4-oxo-3-phenyl-butanoic acid A-3 (13 g, 45.0 mmol, 1 equiv.) in ethanol (344 mL) was added hydrazine hydrate (90.1 mmol, 4.5 mL, 98% purity, 2 equiv.). The mixture was then stirred at 80° C. for 16 h. The mixture was cooled and filtered. The filter cake was dried to give 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyridazin-6-one A-4 (10.1 g, crude) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=11.22(s,1H),7.74(d,J=8.8Hz,2H),7.44(d,J=8.8Hz,2H),7.35-7.29(m,2H),7. 27-7.22(m,1H),7.20-7.16(m,2H),4.68(d,J=7.2Hz,1H),3.09(m,1H),2.47(s,1H).
[0098] Step 4: Synthesis of intermediate I-1 To a solution of 3-(4-chlorophenyl)-4-phenyl-4,5-dihydro-1H-pyridazin-6-one A-4 (1 g, 3.5 mmol, 1 equiv.) in tetrahydrofuran (10 mL), lithium aluminum hydride (400 mg, 10.5 mmol, 3 equiv.) was added at 0° C. Then the mixture was stirred at 70° C. for 1 h. The mixture was filtered and the filtrate was concentrated to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate, 5:1) to give the product 3-(4-chlorophenyl)-4-phenyl-1,4,5,6-tetrahydropyridazine (intermediate I-1, 730 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=7.67(s,1H),7.50-7.43(m,2H),7.32-7.12(m,7H),4.15(d,J=4.4Hz,1 H),3.10-3.03(m,1H),2.92(m,1H),2.19-2.06(m,1H),1.87-1.77(m,1H).
[0099] Example 2 - Synthesis of intermediate I-2 Some of the intermediates I-2 defined below may be commercially available, others may be prepared through a variety of procedures. Schemes 2-4 show three procedures that may be used to prepare intermediate I-2.
[0100] (a) Step 1 (Scheme 2): [ka] iN-(4-chlorophenyl)sulfonylcarbamic acid methyl ester (R 3 =4-Cl-Ph) 4-Chlorobenzenesulfonamide (R 3 To a solution of N-(4-Cl-Ph, 5 g, 26.1 mmol, 1 equiv.) and potassium carbonate (10.4 g, 74.9 mmol, 2.87 equiv.) was added methyl chloroformate (36.53 mmol, 2.8 mL, 1.4 equiv.) at 0° C. The mixture was then stirred at 25° C. for 2 h. The pH was then adjusted to 3 with 1 M hydrochloric acid (50 mL) and the mixture was extracted with 90 mL of ethyl acetate (3×30 mL). The organic phase was then washed with brine (50 mL), dried over anhydrous sodium sulfate and concentrated to give the crude product methyl N-(4-chlorophenyl)sulfonylcarbamate I-2 (R 3 = 4-Cl-Ph, 5.8 g) was obtained as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=12.61-11.72(m,1H),7.91(d,J=8.8Hz,2H),7.70(d,J=8.8Hz,2H),3.58(s,3H).
[0101] ii. Methyl N-(3,5-difluorophenyl)sulfonylcarbamate (R 3 =3,5-F 2 -Ph) 3,5-Difluorobenzenesulfonamide (R 3 =3,5-F 2To a solution of N-(3,5-difluorophenyl)sulfonylcarbamate I-2 (R 2H 2 O, 2 g, 10.35 mmol, 1 equiv.) was added triethylamine (31.06 mmol, 4.3 mL, 3 equiv.) at 0° C. and stirred at 0° C. for 10 min. Then, methyl chloroformate (1.17 g, 12.42 mmol, 0.96 mL, 1.2 equiv.) was added to the mixture at 0° C. The mixture was stirred at 0° C. for 30 min, then warmed to 25° C. and stirred for 2 h. The mixture was diluted with aqueous sodium bicarbonate (30 mL), extracted with dichloromethane (30 mL×3), and washed with brine (5 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum to give the crude product, methyl N-(3,5-difluorophenyl)sulfonylcarbamate I-2 (R 2H 2 O, 2 g, 10.35 mmol, 1 equiv.). 3 =3,5-F 2 -Ph, 4.4 g, crude) as a yellow solid. 1 H NMR (400 MHz, chloroform-d) δ = 7.52-7.44 (m, 2H), 6.92-6.84 (m, 1H), 3.58-3.53.
[0102] iii. Methyl N-[5-(trifluoromethyl)-2-pyridyl]sulfonylcarbamate (R 3 =5-CF 3 -2-Py) To a solution of 5-(trifluoromethyl)pyridine-2-sulfonamide (1 g, 4.42 mmol, 1 equiv.) and potassium carbonate (1.8 g, 12.7 mmol, 2.87 equiv.) in acetone (10 mL) and water (2 mL) was added methyl chloroformate (585 mg, 6.2 mmol, 0.5 mL, 1.4 equiv.) at 0° C. The mixture was then stirred at 25° C. for 2 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give methyl N-[5-(trifluoromethyl)-2-pyridyl]sulfonylcarbamate I-2 (R 3 =5-CF 3 -2-Py, 1.3 g, crude) was obtained as a pale yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=8.96(s,1H),8.32(d,J=8.0Hz,1H),8.05(d,J=8.0Hz,1H),3.30(s,3H).
[0103] (b) Step 2 (Scheme 3) [ka] Step 1 - Synthesis of Compound B-1 A mixture of piperidine (11.7 mmol, 1.2 mL, 1 eq.) and sulfamide (6.8 g, 70.5 mmol, 6 eq.) in dimethoxyethane (10 mL) was stirred at 120° C. for 3 h under microwave. The mixture was concentrated to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate=1:1, Rf=0.4) to give the product piperidine-1-sulfonamide B-1 (1.3 g) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=6.65(s,2H),2.97-2.87(m,4H),1.56(m,4H),1.46-1.39(m,2H).
[0104] Step 2-Intermediate I-2(R 3 Synthesis of N-piperidinyl To a solution of piperidine-1-sulfonamide B-1 (1.3 g, 7.9 mmol, 1 equiv.) and potassium carbonate (3.1 g, 22.7 mmol, 2.87 equiv.) in acetone (9.75 mL) and water (0.65 mL) was added methyl chloroformate (11.1 mmol, 0.86 mL, 1.4 equiv.) at 0° C. The mixture was then stirred at 25° C. for 2 h. The pH was then adjusted to 3 with 1 M hydrochloric acid (30 mL) and the mixture was extracted with 90 mL of ethyl acetate (3×30 mL). The organic phase was then washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure to give the crude product N-(1-piperidylsulfonyl)methylcarbamate (1.8 g, crude) as a yellow oil. 1 H NMR (400MHz, DMSO-d 6 )δ=11.23(s,1H),3.64(s,3H),3.23-3.13(m,4H),1.57-1.44(m,6H).
[0105] (c) Step 3 (Scheme 4) [ka] iN-[(4,4-difluoro-1-piperidyl)sulfonyl]carbamic acid methyl ester (R 3 =4,4-F 2 -piperidinyl) To a solution of N-(oxomethylene)sulfamoyl chloride, also known as chlorosulfonyl isocyanate (18.2 mmol, 1.6 mL, 1.1 equiv.) in dichloromethane (16 mL) was added a solution of methanol (18.2 mmol, 0.7 mL, 1.1 equiv.) in dichloromethane (3 mL) under nitrogen at −10° C. and the mixture was stirred at −10° C. for 1 h. A solution of 4,4-difluoropiperidine (2 g, 16.5 mmol, 1 equiv.) and triethylamine (33.0 mmol, 4.6 mL, 2 equiv.) in dichloromethane (3 mL) was added at −10° C. and the mixture was stirred at 25° C. for 15 h. The mixture was concentrated to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate=1:1) to give the product N-[(4,4-difluoro-1-piperidyl)sulfonyl]carbamate methyl ester (1.4 g) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=11.54(br s,1H),3.67(s,3H),3.40-3.35(m,4H),2.19-1.99(m,4H).
[0106] ii. Methyl N-[(3,3-difluoro-1-piperidyl)sulfonyl]carbamate (R 3 =3,3-F 2 -piperidinyl) To a solution of N-(oxomethylene)sulfamoyl chloride (14.0 mmol, 1.2 mL, 1.1 equiv) in dichloromethane (16 mL) was added a solution of methanol (14.0 mmol, 0.56 mL, 1.1 equiv) in dichloromethane (3 mL) under nitrogen at −10° C. and the mixture was stirred at −10° C. for 1 h. A solution of 3,3-difluoropiperidine (2.00 g, 12.69 mmol, 1 equiv, HCl) and triethylamine (38.1 mmol, 5.3 mL, 3 equiv) in dichloromethane (3 mL) was added at −10° C. and the mixture was stirred at 25° C. for 15 h. The mixture was concentrated to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate=1:1) to give the product N-[(3,3-difluoro-1-piperidyl)sulfonyl]carbamate methyl ester (1.1 g) as a yellow oil. 1 H NMR (400MHz, DMSO-d 6 )δ=11.74(s,1H),3.66(s,3H),3.52(t,J=11.6Hz,2H),3.30-3.22(m,2H),2.08-2.00(m,2H),1.80-1.66(m,2H).
[0107] Example 3 - Synthesis of Compounds 1-8 and Separation of Isomers Scheme 5 shows the general chemical synthesis of the present compounds, such as compounds 1-8, and the separation of their isomers. Note that the isomers are numbered hereinafter as isomers 1 and 2 according to the order in which they occur during the chiral separation as presented below. This numbering should not be taken as an introduction to the A or B compound structures described herein, and does not relate to the order of stereochemistry shown in Scheme 5, unless otherwise indicated. [ka]
[0108] (a) Compound 1 R 3 Compound 1 (and its isomers) in which is a 4-chlorophenyl group is prepared according to the following procedure.
[0109] i. Intermediate I-3(R 3 = 4-chlorophenyl) A mixture of intermediate I-2 (Example 2(a)(i), 554.3 mg, 2.2 mmol, 1.2 equiv.) and intermediate I-1 (Example 1, 500 mg, 1.9 mmol, 1 equiv.) in toluene (20 mL) was stirred at 120° C. for 16 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate=5:1) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboxamide (800 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=11.23(s,1H),8.05(d,J=8.8Hz,2H),7.89(d,J=8.8Hz,2H),7.74(d,J=8.8Hz,2H),7.42(d,J=8.8Hz,2H),7.35-7.27(m,2H),7. 26-7.18(m,1H),7.13(d,J=7.2Hz,2H),4.46(d,J=3.2Hz,1H),3.97(d,J=13.2Hz,1H),2.90(m,1H),2.17-2.05(m,1H),1.94(m,1H).
[0110] ii. Intermediate I-4(R 3 = 4-chlorophenyl) To a solution of intermediate I-3 from step (i) (400 mg, 819.0 μmol, 1 equiv.) in acetonitrile (10 mL), phosphorus oxychloride (2.9 mmol, 0.27 mL, 3.5 equiv.) was added and the mixture was stirred at 25° C. for 0.5 h. Then, 2,6-lutidine (3.3 mmol, 0.38 mL, 4 equiv.) was added and the mixture was stirred at 80° C. for 15.5 h. The mixture was poured into aqueous sodium bicarbonate (20 mL) and extracted with 60 mL of ethyl acetate (3×20 mL). The organic phase was then washed with brine (20 mL), dried over anhydrous sodium sulfate, and concentrated to give intermediate I-4(2E)-6-(4-chlorophenyl)-N-(4-chlorophenyl)sulfonyl-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (400 mg, crude) as a brown solid.
[0111] iii.Compound 1(R 3 =4-Chlorophenyl) racemic To a solution of N-carbamimidoylacetamide (279 mg, 2.8 mmol, 4 equiv.) and intermediate I-4 from step (ii) (350 mg, 690.6 μmol, 1 equiv.) in N,N-dimethylformamide (3.5 mL) was added N,N-diisopropylethylamine (3.5 mmol, 0.60 mL, 5 equiv.) The mixture was then stirred at 25° C. for 2 h. The mixture was purified by preparative HPLC (Column: Waters Xbridge™ 150×25 mm, 5 um, Mobile phase: [Water (10 mM ammonium bicarbonate)-acetonitrile], B%: 49%-79%, 10 min), then the fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 1, i.e., N-[(E)-N′-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-(4-chlorophenyl)sulfonylcarbonimidoyl]carbamimidoyl]acetamide (180 mg) as a white solid.
[0112] iv.Compound 1(R 3 = 4-chlorophenyl) isomer separation The racemic product of step (iii) was purified by SFC (column: DAICEL CHIRALPAK™ AD (250 mm × 30 mm, 10 μm), mobile phase: CO 2 in 60% isopropanol (0.1% ammonia monohydrate), 3; 50 min) to give isomers 1 and 2 of compound 1 with the following properties:
[0113] Isomer 1 (61 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.67(s,1H),8.34-7.70(m,4H),7.54(d,J=8.4Hz,4H),7.33-7.26(m,4H),7.25-7.14(m,3H),4.3 8(d,J=3.2Hz,1H),4.31-4.22(m,1H),3.23-3.12(m,1H),2.28-2.18(m,1H),2.13(s,3H),1.97(m,1H). LCMS: (ES + ) m / z = 571.1 (M+H), R t =1.004 minutes. SFC:ee value > 99%, R t =0.754 minutes.
[0114] Isomer 2 (51 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.66(s,1H),8.36-7.72(m,4H),7.54(d,J=8.8Hz,4H),7.32-7.27(m,4H),7.25-7.15(m,3H),4.3 8(d,J=3.2Hz,1H),4.30-4.22(m,1H),3.23-3.11(m,1H),2.30-2.17(m,1H),2.13(s,3H),1.97(m,1H). (M+H), R t =1.009 minutes. SFC:ee value > 99%, R t =1.543 minutes.
[0115] (b) Compound 2 R3 Compound 2 (and its isomers) in which is an N-piperidinyl group is prepared according to the following procedure.
[0116] i. Intermediate I-3(R 3 =N-piperidinyl) A mixture of intermediate I-2 (Example 2(b), 493.4 mg, 2.22 mmol, 1.2 equiv.) and intermediate I-1 (Example 1, 500 mg, 1.9 mmol, 1 equiv.) in toluene (20 mL) was stirred at 120° C. for 16 h. The mixture was concentrated under reduced pressure to give a residue. The residue was triturated with ethanol (10 mL) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-5-phenyl-N-(1-piperidylsulfonyl)-4,5-dihydro-3H-pyridazine-2-carboxamide (800 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.24(s,1H),7.85(d,J=8.8Hz,2H),7.39(d,J=8.8Hz,2H),7.35-7.29(m,2H),7.26-7.21(m,1H),7.16(d,J=7.2Hz,2H), 4.48(d,J=3.2Hz,1H),4.09(d,J=13.2Hz,1H),3.32-3.28(m,4H),2.97(m,1H),2.17(m,1H),1.99(m,1H),1.64-1.45(m,6H).
[0117] ii. Intermediate I-4(R 3 =N-piperidinyl) To a solution of intermediate I-3 from step (i) (400 mg, 867.7 μmol, 1 equiv) in acetonitrile (10 mL) was added phosphorus oxychloride (3.0 mmol, 0.28 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.5 mmol, 0.40 mL, 4 equiv) was added and the mixture was stirred at 80° C. for 15.5 h. The mixture was poured into aqueous sodium bicarbonate (20 mL) and extracted with 60 mL of ethyl acetate (3×20 mL). The organic phase was then washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4, i.e., (2E)-6-(4-chlorophenyl)-5-phenyl-N-(1-piperidylsulfonyl)-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (450 mg, crude) as a brown solid.
[0118] iii.Compound 2(R 3 =N-piperidinyl) racemic To a solution of N-carbamimidoylacetamide (337.4 mg, 3.3 mmol, 4 equiv.) and intermediate I-4 from step (ii) (400 mg, 834.3 μmol, 1 equiv.) in N,N-dimethylformamide (4 mL) was added N,N-diisopropylethylamine (4.2 mmol, 0.73 mL, 5 equiv.) The mixture was then stirred at 25° C. for 2 h. The mixture was purified by preparative HPLC (column: Waters Xbridge™ 150×25 mm, 5 μm, mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile], B%: 42%-72%, 9 min), then the fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 2, i.e., N-[(E)-N′-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-(1-piperidylsulfonyl)carbonimidoyl]carbamimidoyl]acetamide (120 mg) as a white solid.
[0119] iv.Compound 2(R 3 =N-piperidinyl) isomer separation The racemic product from step (iii) was purified by SFC (column: DAICEL CHIRALPAK™ AD (250 mm×30 mm, 10 μm), mobile phase: CO 2 in 60% isopropanol (0.1% ammonia monohydrate), 4.3 min, 60 min) to give isomers 1 and 2 of compound 2 with the following properties:
[0120] Isomer 1 (54 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.84(s,1H),7.64(d,J=8.8Hz,2H),7.40-7.33(m,4H),7.32-7.22(m,3H),4.43(d,J=3.2Hz,1H),4.34-4.27(m,1H),3.18(br s,1H),3.10-3.02(m,4H),2.41-2.27(m,1H),2.21(s,3H),2.03(d,J=11.6Hz,1H),1.60(br s,4H),1.48(d,J=4.4Hz,2H). LCMS: (ES + ) m / z = 544.2 (M + H), R t =0.992 minutes. SFC:ee value > 99%, R t =0.616 minutes.
[0121] Isomer 2 (52 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.84(s,1H),7.64(d,J=8.8Hz,2H),7.40-7.34(m,4H),7.31-7.23(m,3H),4.43(d,J=3.6Hz,1H),4.31(d,J =12.8Hz,1H),3.25-3.14(m,1H),3.11-3.04(m,4H),2.37-2.27(m,1H),2.21(s,3H),2.07-1.99(m,1H),1.60(br s,4H),1.48(d,J=4.4Hz,2H). LCMS: (ES + ) m / z = 544.2 (M + H), R t=0.992 minutes. SFC:ee value > 99%, R t =2.235 minutes.
[0122] (c) Compound 3 R 3 Compound 3 (and its isomers) in which is an N-(4-trifluoromethyl-1-piperidinyl) group is prepared according to the following procedure.
[0123] i. Intermediate I-2(R 3 = 4-trifluoromethyl-1-piperidinyl) A mixture of intermediate I-3 (500 mg, 1.7 mmol, 1 equiv.) and methyl N-[[4-(trifluoromethyl)-1-piperidyl]sulfonyl]carbamate as intermediate I-1 (Example 1, 560 mg, 2.1 mmol, 1.2 equiv.) in toluene (20 mL) was stirred at 120° C. for 16 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica gel column (petroleum ether:ethyl acetate=5:1, R f =0.5) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-5-phenyl-N-[[4-(trifluoromethyl)-1-piperidyl]sulfonyl]-4,5-dihydro-3H-pyridazine-2-carboxamide (840 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.41(s,1H),7.86(d,J=8.8Hz,2H),7.39(d,J=8.8Hz,2H),7.34-7. 29(m,2H),7.26-7.20(m,1H),7.15(d,J=7.2Hz,2H),4.48(d,J=2.8Hz,1H ),4.12-4.03(m,1H),3.86(t,J=9.6Hz,2H),3.10-2.87(m,4H),2.23-2. 11(m,1H),2.06-1.96(m,1H),1.90(d,J=11.6Hz,2H),1.57-1.41(m,2H).
[0124] ii. Intermediate I-4(R 3 = 4-trifluoromethyl-1-piperidinyl) To a solution of intermediate I-3 from step (i) (400 mg, 756.2 μmol, 1 equiv) in acetonitrile (10 mL) was added phosphorus oxychloride (2.6 mmol, 0.25 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.0 mmol, 0.35 mL, 4 equiv) was added and the mixture was stirred at 80° C. for 15.5 h. The mixture was poured into aqueous sodium bicarbonate (20 mL) and extracted with 60 mL of ethyl acetate (3×20 mL). The organic phase was then washed with brine (20 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4, i.e., (2E)-6-(4-chlorophenyl)-5-phenyl-N-[[4-(trifluoromethyl)-1-piperidyl]sulfonyl]-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (470 mg, crude) as a brown solid.
[0125] iii.Compound 3(R 3 =4-trifluoromethyl-1-piperidinyl) racemic To a solution of N-carbamimidoylacetamide (347.4 mg, 3.4 mmol, 4 equiv.) and intermediate I-4 from step (ii) (470 mg, 858.6 μmol, 1 equiv.) in N,N-dimethylformamide (5 mL) was added N,N-diisopropylethylamine (4.3 mmol, 0.75 mL, 5 equiv.) The mixture was then stirred at 25° C. for 2 h. The mixture was purified by preparative HPLC (column: Waters Xbridge™ 150×25 mm, 5 μm, mobile phase: [water (10 mM ammonium bicarbonate)-acetonitrile], B%: 48%-78%, 9 min), then the fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 3, i.e., N-[(E)-N′-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-[[4-(trifluoromethyl)-1-piperidyl]sulfonyl]carbimidoyl]carbamidoyl]acetamide (180 mg) as a white solid.
[0126] iv.Compound 3(R 3= 4-Trifluoromethyl-1-piperidinyl) isomer separation The racemic product from step (iii) was purified by SFC (column: DAICEL CHIRALPAK™ AD (250 mm×30 mm, 10 μm), mobile phase: CO 2 in 50% isopropanol (0.1% ammonia monohydrate), 3.6 min, 40 min) to give isomers 1 and 2 of compound 3 with the following properties:
[0127] Isomer 1 (80 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.80(s,1H),8.35-7.78(m,2H),7.58(d,J=8.8Hz,2H),7.35-7.28(m,4 H),7.26-7.16(m,3H),4.38(d,J=3.2Hz,1H),4.24(d,J=13.2Hz,1H),3.69- 3.58(m,2H),3.18-3.05(m,1H),2.64(d,J=12.4Hz,2H),2.45-2.21(m,2H), 2.15(s,3H),2.03-1.90(m,1H),1.83(d,J=12.8Hz,2H),1.59-1.41(m,2H). LCMS: (ES + ) m / z = 612.1 (M+H), R t =1.049 minutes. SFC:ee value > 99%, R t =0.537 minutes.
[0128] Isomer 2 (75 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6)δ=10.86(s,1H),8.42-7.79(m,2H),7.64(d,J=8.8Hz,2H),7.40-7.34(m,4H),7.32-7.23(m,3H),4.44(br d,J=3.2Hz,1H),4.31(d,J=13.2Hz,1H),3.78-3.62(m,2H),3.24-3.11(m,1H),2.78-2.65(m,2H) ),2.53-2.27(m,2H),2.21(s,3H),2.05-1.97(m,1H),1.90(d,J=12.4Hz,2H),1.65-1.50(m,2H). LCMS: (ES + ) m / z = 612.1 (M+H), R t =1.041 minutes. SFC:ee value > 99%, R t =1.134 minutes.
[0129] (d) Compound 4 R 3 Compound 4 (and its isomers) in which is an N-(4,4-difluoro-1-piperidinyl) group is prepared according to the following procedure.
[0130] i. Intermediate I-3(R 3 = 4,4-difluoro-1-piperidinyl) A mixture of intermediate I-2 (Example 2(c)(i), 500 mg, 1.9 mmol, 1 equiv.) and intermediate I-1 (Example 1, 524.2 mg, 1.9 mmol, 1.2 equiv.) in toluene (5 mL) was stirred at 120° C. for 5 h. The mixture was concentrated under reduced pressure to give a residue. The residue was triturated with ethanol (10 mL) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-N-[(4,4-difluoro-1-piperidyl)sulfonyl]-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboxamide (800 mg) as a white solid. 1 H NMR (400MHz, DMSO-d 6)δ=10.56(s,1H),7.92-7.82(m,2H),7.40(d,J=8.8Hz,2H),7.35-7.30(m,2H),7.26-7.21(m,1H),7.16(d,J=7.2 Hz,2H),4.48(d,J=3.2Hz,1H),4.10(d,J=12.8Hz,1H),3.50(m,4H),2.98(m,1H),2.23-2.03(m,5H),1.99(m,1H).
[0131] ii. Intermediate I-4(R 3 = 4,4-difluoro-1-piperidinyl) To a solution of intermediate I-3 from step (i) (400 mg, 804.9 μmol, 1 equiv) in acetonitrile (5 mL) was added phosphorus oxychloride (2.8 mmol, 0.26 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.2 mmol, 0.37 mL, 4 equiv) was added and the mixture was stirred at 80° C. for 15.5 h. The mixture was poured into water (20 mL) and extracted with 30 mL of ethyl acetate (3×10 mL). The organic phase was then washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4, i.e., (2E)-6-(4-chlorophenyl)-N-[(4,4-difluoro-1-piperidyl)sulfonyl]-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (360 mg, crude) as a yellow solid.
[0132] iii.Compound 4(R 3 =4,4-Difluoro-1-piperidyl) racemic To a solution of N-carbamimidoylacetamide (243.3 mg, 2.4 mmol, 4 equiv.) and intermediate I-4 from step (ii) (310 mg, 601.5 μmol, 1 equiv.) in N,N-dimethylformamide (3 mL) was added N,N-diisopropylethylamine (3.01 mmol, 0.52 mL, 5 equiv.), and the mixture was then stirred at 25° C. for 16 h. The mixture was purified by preparative HPLC (column: Waters Xbridge™ 150×25 mm, 5 μm, mobile phase: [water (ammonium bicarbonate)-acetonitrile], B%: 50%-80%, 10 min), then the fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 4, i.e., N-[(E)-N′-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-[(4,4-difluoro-1-piperidyl)sulfonyl]carbonimidoyl]carbamimidoyl]acetamide (170 mg) as a yellow solid.
[0133] iv.Compound 4(R 3 = 4,4-difluoro-1-piperidinyl) isomer separation The racemic product from step (iii) was purified by SFC (column: DAICEL CHIRALPAK™ AD (250 mm×30 mm, 10 μm), mobile phase: CO 2 in 45% isopropanol (0.1% ammonia monohydrate), 7.5 min, 90 min) to give isomers 1 and 2 of compound 4 with the following properties:
[0134] Isomer 1 as a white solid (45 mg, 99.1% purity). 1 H NMR (400MHz, DMSO-d 6)δ=10.83(br s,1H),8.52-7.69(m,2H),7.58(d,J=8.8Hz,2H),7.35-7.28(m,4H),7.26-7.17(m,3H),4.39(d,J=3.6Hz,1H),4.19( d,J=13.2Hz,1H),3.22(t,J=5.2Hz,4H),3.12(t,J=11.6Hz,1H),2.31-2.20(m,1H),2.16(s,3H),2.11-1.94(m,5H). LCMS: (ES + ) m / z = 580.1 (M+H), R t =1.000 minutes. SFC:ee value > 99%, R t =1.793 minutes.
[0135] Isomer 2 as a white solid (40 mg, 100% pure). 1 H NMR (400MHz, DMSO-d 6 )δ=10.83(s,1H),8.52-7.72(m,2H),7.58(d,J=8.8Hz,2H),7.35-7.28(m,4H),7.26-7.16(m,3H),4.39(d,J=3.2Hz,1H ),4.19(d,J=13.2Hz,1H),3.22(t,J=5.2Hz,4H),3.17-3.07(m,1H),2.31-2.20(m,1H),2.16(s,3H),2.13-1.95(m,5H). LCMS: (ES + ) m / z = 580.1 (M+H), R t =1.003 minutes. SFC:ee value > 99%, R t =2.257 minutes.
[0136] (e) Compound 5 R 3 Compound 5 (and its isomers) in which is an N-(3,3-difluoro-1-piperidinyl) group is prepared according to the following procedure.
[0137] i. Intermediate I-3(R 3 =3,3-difluoro-1-piperidinyl) A mixture of intermediate I-2 (Example 2(c)(ii), 500 mg, 1.94 mmol, 1 equiv.) and intermediate I-1 (Example 1, 524.2 mg, 1.9 mmol, 1 equiv.) in toluene (5 mL) was stirred at 120° C. for 5 h. The mixture was concentrated under reduced pressure to give a residue. The residue was purified by silica column (petroleum ether:ethyl acetate=1:1) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-N-[(3,3-difluoro-1-piperidyl)sulfonyl]-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboxamide (800 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=10.59(s,1H),7.88(d,J=8.8Hz,2H),7.40(d,J=8.8Hz,2H),7.36-7.29( m,2H),7.24(d,J=7.2Hz,1H),7.16(d,J=7.2Hz,2H),4.49(d,J=2.8Hz,1H),4 .10(d,J=13.2Hz,1H),3.64(t,J=11.6Hz,2H),3.41-3.35(m,2H),2.98(m,1H) ),2.53(d,J=1.6Hz,1H),2.16(m,1H),2.11-2.02(m,2H),1.82-1.71(m,2H).
[0138] ii. Intermediate I-4(R 3 =3,3-difluoro-1-piperidinyl) To a solution of intermediate I-3 from step (i) (400 mg, 804.9 μmol, 1 equiv) in acetonitrile (5 mL) was added phosphorus oxychloride (2.8 mmol, 0.26 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.2 mmol, 0.37 mL, 4 equiv) was added and the mixture was stirred at 80° C. for 15.5 h. The mixture was poured into water (20 mL) and extracted with 30 mL of ethyl acetate (3×10 mL). The organic phase was then washed with brine (30 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4, i.e., (2E)-6-(4-chlorophenyl)-N-[(3,3-difluoro-1-piperidyl)sulfonyl]-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (400 mg, crude) as a yellow solid.
[0139] iii.Compound 5(R 3 =3,3-Difluoro-1-piperidyl) racemic To a solution of N-carbamimidoylacetamide (274.5 mg, 2.7 mmol, 4 equiv.) and intermediate I-4 from step (ii) (350 mg, 679.1 μmol, 1 equiv.) in N,N-dimethylformamide (3 mL) was added N,N-diisopropylethylamine (3.4 mmol, 0.59 mL, 5 equiv.), and the mixture was then stirred at 25° C. for 16 h. The mixture was purified by preparative HPLC (column: Waters Xbridge™ 150×25 mm, 5 μm, mobile phase: [water (ammonium bicarbonate)-acetonitrile], B%: 48%-78%, 10 min), then the fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 5, i.e., N-[(E)-N′-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-[(3,3-difluoro-1-piperidyl)sulfonyl]carbonimidoyl]carbamimidoyl]acetamide (140 mg) as a yellow solid.
[0140] iv.Compound 5(R 3 =3,3-Difluoro-1-piperidinyl) isomer separation The racemic product from step (iii) was purified by SFC (column: DAICEL CHIRALCEL™ OD (250 mm×30 mm, 10 μm), mobile phase: CO 2 in 30% methanol (0.1% ammonia monohydrate), 3.0 min, 50 min) to give isomers 1 and 2 of compound 5 with the following properties:
[0141] Isomer 1 as a white solid (35 mg, 99.5% purity). 1 H NMR (400MHz, DMSO-d 6 )δ=10.83(br s,1H),8.58-7.70(m,2H),7.58(d,J=8.8Hz,2H),7.35-7.28(m,4H),7.26-7.17(m,3H),4.39(d,J=3.2Hz,1H),4.26(d,J=13.2Hz) ,1H),3.28(t,J=12.0Hz,2H),3.19-3.12(m,1H),3.11-3.05(m,2H),2.31-2.21(m,1H),2.16(s,3H),2.04-1.90(m,3H),1.71(br s,2H). LCMS: (ES + ) m / z = 580.1 (M+H), R t =1.008 minutes. SFC:ee value > 99%, R t =1.467 minutes.
[0142] Isomer 2 as a white solid (48 mg, 99.2% purity). 1 H NMR (400MHz, DMSO-d 6 )δ=10.84(br s,1H),8.56-7.72(m,2H),7.58(d,J=8.8Hz,2H),7.35-7.28(m,4H),7.26-7.16(m,3H),4.39(d,J=3.2Hz,1H),4.26(d,J=13.2Hz) ,1H),3.28(t,J=11.6Hz,2H),3.19-3.12(m,1H),3.11-3.03(m,2H),2.31-2.22(m,1H),2.16(s,3H),2.05-1.88(m,3H),1.71(br s,2H). LCMS: (ES + ) m / z = 580.1 (M+H), R t =1.003 minutes. SFC:ee value > 99%, R t =1.648 minutes.
[0143] (f) Compound 6 R 3 Compound 6 (and its isomers) in which is a 3,5-difluorophenyl group is prepared according to the following procedure.
[0144] i. Intermediate I-3(R 3 = 3,5-difluorophenyl) A mixture of intermediate I-2 (Example 2(a)(ii), 510.29 mg, 2.03 mmol, 1.1 equiv.) and intermediate I-1 (Example 1, 0.5 g, 1.85 mmol, 1 equiv.) in toluene (5 mL) was stirred at 120° C. for 12 h. The mixture was diluted with water (10 mL) and extracted with EtOAc (10 mL×2). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under vacuum. The residue was purified by silica column chromatography (petroleum ether:ethyl acetate=2:1) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-N-(3,5-difluorophenyl)sulfonyl-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboxamide (0.5 g) as a brown solid. 1 H NMR (400MHz, DMSO-d 6 )δ=9.29(s,1H),7.74(d,J=4.2Hz,2H),7.53(d,J=8.6Hz,2H),7.36-7.28(m ,5H),7.13-7.02(m,4H),4.24-4.18(m,2H),3.08(m,1H),2.18-2.09(m,2H).
[0145] Intermediate I-4(R 3 = 3,5-difluorophenyl) To a solution of intermediate I-3 from step (i) (0.5 g, 1.02 mmol, 1 equiv.) in acetonitrile (5 mL), phosphorus oxychloride (548 mg, 3.57 mmol, 0.33 mL, 3.5 equiv.) was added and the mixture was stirred at 25° C. for 0.5 h. Then, 2,6-lutidine (437 mg, 4.08 mmol, 0.47 mL, 4 equiv.) was added and the mixture was stirred at 40° C. for 2 h. The mixture was added dropwise to water (10 mL) and extracted with 30 mL of ethyl acetate (3×10 mL). The organic phase was then dried over anhydrous sodium sulfate and concentrated to give intermediate I-4(2E)-6-(4-chlorophenyl)-N-(3,5-difluorophenyl)sulfonyl-5-phenyl-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (0.5 g, crude) as a brown solid.
[0146] iii.Compound 6(R 3 =3,5-difluorophenyl) racemic To a solution of N-carbamimidoylacetamide (89 mg, 885 μmol, 3 equiv.) and intermediate I-4 from step (ii) (150 mg, 295.1 μmol, 1 equiv.) in N,N-dimethylformamide (1.5 mL), N,N-diisopropylethylamine (1.48 mmol, 0.25 mL, 5 equiv.) was added. The mixture was then stirred at 25° C. for 12 h. The mixture was diluted with water (5 mL) and extracted with ethyl acetate (5 mL×3). The organic layer was concentrated under vacuum. The residue was purified by preparative HPLC (0.1% M ammonium hydroxide) and the fractions were then lyophilized to give racemic compound 6, i.e., N-[(E)-N'-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-(3,5-difluorophenyl)sulfonylcarbonimidoyl]carbamimidoyl]acetamide (50 mg) as a white solid.
[0147] iv.Compound 1(R 3 =3,5-difluorophenyl) isomer separation The racemic product of step (iii) was separated by SFC (column: DAICEL CHIRALCEL™ OD (250 mm×30 mm, 10 μm); mobile phase: [Neu-MeOH]; B%: 40%, 3.5; 35 min) to give isomers 1 and 2 of compound 6 with the following properties:
[0148] Isomer 1 as an off-white solid (27 mg, 98.8% purity). 1 H NMR (400MHz, methanol-d 4 )δ=7.57(d,J=8.8Hz,2H),7.49(d,J=4.8Hz,2H),7.34-7.28(m,2H),7.24(d,J=7.2Hz,1H),7.21- 7.12(m,5H),4.59(s,2H),4.44-4.29(m,2H),2.37-2.25(m,1H),2.14(s,3H),2.09-2.05(m,1H). 19 F NMR (377MHz, methanol-d 4 ) δ = -110.05 (br s, 1F) LCMS: (ES + ) m / z = 573.2 (M + H), R t =0.895 minutes. SFC: ee value 97.88%, R t =1.445 minutes.
[0149] Isomer 2 (31 mg) as an off-white solid. 1 H NMR (400MHz, methanol-d 4 )δ=7.57(d,J=8.8Hz,2H),7.50-7.49(m,2H),7.33-7.28(m,2H),7.24(d,J=7.2Hz,1H),7.21-7 .14(m,5H),4.59(s,2H),4.44-4.30(m,2H),2.42-2.25(m,1H),2.14(s,3H),2.09-2.05(m,1H). 19 F NMR (377MHz, methanol-d 4 ) δ = -110.05 (br s, 1F) LCMS: (ES + ) m / z = 573.2 (M + H), R t =0.887 minutes. SFC:ee value > 99%, R t =1.784 minutes.
[0150] (g) Compound 7 R 3 Compound 7 (and its isomers) in which is a 4-trifluoromethylphenyl group is prepared according to the following procedure.
[0151] i. Intermediate I-3(R 3 = 4-trifluoromethylphenyl) A mixture of intermediate I-2, N-[4-(trifluoromethyl)phenyl]sulfonyl methyl carbamate (500 mg, 1.8 mmol, 1 eq.), prepared by a known process, and intermediate I-1 (Example 1, 478 mg, 1.8 mmol, 1 eq.) in toluene (10 mL) was stirred at 120° C. for 12 hours. After cooling, the mixture was concentrated under reduced pressure to obtain a residue. The residue was triturated with ethanol (10 mL), then filtered, and the filter cake was dried to obtain intermediate I-3, i.e., 6-(4-chlorophenyl)-5-phenyl-N-[(4-trifluoromethyl)phenyl]sulfonyl-4,5-dihydro-3H-pyridazine-2-carboxamide (650 mg) as a pale yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=11.43(br s,1H),8.26(d,J=8.4Hz,2H),8.06(d,J=8.4Hz,2H),7.89(d,J=8.4Hz,2H),7.43(d, J=8.4Hz,2H),7.35-7.27(m,2H),7.26-7.18(m,1H),7.13(d,J=7.6Hz,2H),4.47(br d,J=3.2Hz,1H),3.97(d,J=12.8Hz,1H),2.90(dt,J=3.6,13.2Hz,1H),2.12(m,1H),2.00-1.89(m,1H).
[0152] ii. Intermediate I-4(R 3= 4-trifluoromethylphenyl) To a solution of intermediate I-3 from step (i) (400 mg, 766.4 μmol, 1 equiv) in acetonitrile (4 mL) was added phosphorus oxychloride (2.7 mmol, 0.25 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.07 mmol, 0.36 mL, 4 equiv) was added and the mixture was stirred at 60° C. for 2.5 h. The mixture was poured into water (10 mL) and extracted with 15 mL of ethyl acetate (3×5 mL). The organic phase was then washed with brine (10 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4, i.e., (2E)-6-(4-chlorophenyl)-5-phenyl-N-[4-(trifluoromethyl)phenyl]sulfonyl-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (500 mg, crude) as a brown solid.
[0153] iii.Compound 7(R 3 =4-trifluoromethylphenyl) racemic To a solution of N-carbamimidoylacetamide (337 mg, 3.33 mmol, 4 equiv.) and intermediate I-4 from step (ii) (450 mg, 832 μmol, 1 equiv.) in N,N-dimethylformamide (4.5 mL), N,N-diisopropylethylamine (4.16 mmol, 0.72 mL, 5 equiv.) was added. The mixture was then stirred at 25° C. for 1 h. The mixture was purified by preparative HPLC (column: Waters Xbridge™ 150×50 mm, 10 μm; mobile phase: [water (ammonium bicarbonate)-acetonitrile]; B%: 43%-73%, 11 min). The fractions were concentrated to remove acetonitrile and lyophilized to give racemic compound 7, i.e., N-[(E)-N'-[(Z)-C-[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-N-[4-(trifluoromethyl)phenyl]sulfonyl-carbonimidoyl]carbamimidoyl]acetamide (170 mg) as a yellow solid.
[0154] iv. Compound 7(R 3= 4-trifluoromethylphenyl) isomer separation The racemic product from step (iii) was purified by SFC (column: DAICEL CHIRALCEL™ OD (250 mm×30 mm, 10 μm), mobile phase: CO 2 in 40% methanol (0.1% ammonia monohydrate), 3.5 min) to give isomers 1 and 2 of compound 7 with the following properties:
[0155] Isomer 1 as a white solid (38 mg, 99% purity). 1 H NMR (400MHz, methanol-d 4 )δ=8.11(d,J=8.4Hz,2H),7.83(d,J=8.4Hz,2H),7.58(d,J=8.8Hz,2H),7.34-7.29(m,2H),7.25(d,J=7.2Hz,1H), 7.18(m,4H),4.41(m,1H),4.33(d,J=2.8Hz,1H),3.31-3.27(m,1H),2.37-2.26(m,1H),2.14(s,3H),2.09(m,1H). LCMS: (ES + ) m / z = 605.2 (M+H), R t =0.995 minutes. SFC:ee value > 99%, R t =1.551 minutes.
[0156] Isomer 2 as a white solid (38 mg, 99.6% purity). 1 H NMR (400MHz, DMSO-d 6 )δ=8.11(d,J=8.4Hz,2H),7.83(d,J=8.4Hz,2H),7.58(d,J=8.8Hz,2H),7.34-7.28(m,2H),7.25(d,J=7.2Hz,1H),7. 18(m,4H),4.46-4.36(m,1H),4.33(d,J=3.2Hz,1H),3.32-3.26(m,1H),2.37-2.26(m,1H),2.14(s,3H),2.08(m,1H). LCMS: (ES + ) m / z = 605.2 (M+H), R t=0.997 minutes. SFC:ee value > 99%, R t =1.923 minutes.
[0157] (h) Compound 8 R 3 Compound 8 (and its isomers) in which is a 5-(trifluoromethyl)-2-pyridyl group is prepared according to the following procedure.
[0158] i. Intermediate I-3(R 3 = 5-(trifluoromethyl)-2-pyridyl) A mixture of intermediate I-2 (Example 2(a)(iii), 1 g, 3.5 mmol, 1 equiv.) was dissolved in N,N-dimethylformamide (10 mL) and intermediate I-1 (Example 1, 953 mg, 3.5 mmol, 1 equiv.) was added. The mixture was stirred at 120° C. for 2 h. The mixture was poured into water (50 mL) and extracted with 45 mL of ethyl acetate (3×15 mL). The organic layer was then washed with brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a residue. The residue was purified by silica gel column (petroleum ether:ethyl acetate, 1:1) and preparative HPLC (formic acid, 0.1%, 30%-50% acetonitrile) to give intermediate I-3, i.e., 6-(4-chlorophenyl)-5-phenyl-N-[[5-(trifluoromethyl)-2-pyridyl]sulfonyl]-4,5-dihydro-3H-pyridazine-2-carboxamide (520 mg) as a yellow solid. 1 H NMR (400MHz, DMSO-d 6 )δ=12.00(br s,1H),9.23(s,1H),8.60(d,J=7.6Hz,1H),8.35(d,J=8.4Hz,1H),7.97(d,J=8.4Hz,2H),7 .40(d,J=8.4Hz,2H),7.36-7.29(m,2H),7.26-7.20(m,1H),7.14(d,J=7.2Hz,2H),4.47(br s,1H),3.93(d,J=13.2Hz,1H),2.89(m,1H),2.20-2.07(m,1H),1.97-1.87(m,1H).
[0159] ii. Intermediate I-4(R 3 = 5-(trifluoromethyl)-2-pyridyl) To a solution of intermediate I-3 from step (i) (420 mg, 803.2 μmol, 1 equiv) in acetonitrile (4.2 mL) was added phosphorus oxychloride (2.8 mmol, 0.3 mL, 3.5 equiv) and the mixture was stirred at 25° C. for 0.5 h. Then 2,6-lutidine (3.2 mmol, 0.37 mL, 4 equiv) was added and the mixture was stirred at 60° C. for 2.5 h. After cooling, the mixture was poured into water (10 mL) and extracted with 15 mL of ethyl acetate (3×5 mL). The organic phase was then washed with brine (10 mL), dried over anhydrous sodium sulfate and concentrated to give intermediate I-4(2E)-6-(4-chlorophenyl)-5-phenyl-N-[[5-(trifluoromethyl)-2-pyridyl]sulfonyl]-4,5-dihydro-3H-pyridazine-2-carboximidoyl chloride (540 mg, crude) as a yellow solid.
[0160] iii.Compound 8(R 3 = 5-(trifluoromethyl)-2-pyridyl racemic To a solution of N-carbamimidoylacetamide (403 mg, 4 mmol, 4 equiv.) and intermediate I-4 from step (ii) (540 mg, 997.5 μmol, 1 equiv.) in N,N-dimethylformamide (5.4 mL) was added N,N-diisopropylethylamine (5 mmol, 0.87 mL, 5 equiv.). The mixture was then stirred at 25° C. for 2 h. The mixture was poured into water (50 mL). The aqueous mixture was extracted with 90 mL of ethyl acetate (3×30 mL). The organic layers were combined, washed with brine (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give a residue.
[0161] The residue was purified by silica column (petroleum ether: ethyl acetate = 1:1) and preparative HPLC (column: Phenomenex (trademark) Luna C18 150 x 25 mm, 10 μm, mobile phase: [water (formic acid)-acetonitrile]; B%: 45%-75%, 10 min), then the fractions were concentrated to remove acetonitrile and lyophilized to obtain racemic compound 8, i.e., N-[(E)-N-[[6-(4-chlorophenyl)-5-phenyl-4,5-dihydro-3H-pyridazin-2-yl]-[[5-(trifluoromethyl)-2-pyridyl]sulfonylamino]methylene]carbamimidoyl]acetamide (95 mg) as a white solid.
[0162] iv.Compound 8(R 3 = 5-(trifluoromethyl)-2-pyridyl) isomer separation The racemic product of step (iii) was purified by SFC (column: DAICEL CHIRALPAK™ OD (250 mm × 30 mm, 10 μm), mobile phase: CO 2 in 40% methanol (0.1% ammonia monohydrate), 4.6 min) to give isomers 1 and 2 of compound 1 with the following properties:
[0163] Isomer 1 as a white solid (20 mg, 100% pure). 1 H NMR (400MHz, DMSO-d 6 )δ=10.48(br s,1H),9.04(s,1H),8.41(dd,J=1.6,8.4Hz,1H),8.24-7.82(m,2H),7.54(d,J=4.8Hz,2H),7.38-7. 14(m,8H),4.44-4.30(m,2H),3.28-3.20(m,1H),2.29-2.21(m,1H),2.05(s,3H),2.02-1.96(m,1H). LCMS: (ES + ) m / z = 606.2 (M+H), R t =0.950 minutes. SFC:ee value > 99%, R t =1.698 minutes.
[0164] Isomer 2 as a white solid (35 mg, 100% pure). 1 H NMR (400MHz, DMSO-d 6 )δ=10.48(br s,1H),9.04(s,1H),8.41(dd,J=2.0,8.4Hz,1H),8.13(d,J=8.4Hz,2H),7.53(m,2H),7.37-7. 15(m,8H),4.44-4.30(m,2H),3.28-3.20(m,1H),2.31-2.17(m,1H),2.05(s,3H),2.00(m,1H). LCMS: (ES + ) m / z = 606.2 (M+H), R t =0.960 minutes. SFC:ee value > 99%, R t =2.075 minutes.
[0165] Example 4 - Biological properties a) Assay Design Day 1: Using a polyethyleneimine (PEI) transfection agent, HEK293 cells were transfected in suspension with the human CB1 or CB1b receptor and one of the following bioSensAll® assays: GAPL-Gi2, or β-arrestin plasma membrane (PM) translocation biosensor (+GRK2). Cells were seeded directly into 96-well plates immediately after transfection. Day 4 (approximately 65 hours after transfection): Cells were incubated with coelenterazine (luciferase substrate) and different test compounds before measurement of the BRET signal.
[0166] b) Description of the BioSensAll® platform. In this project, i) Gα plasma membrane (GAPL) biosensor and ii) β-arrestin plasma membrane translocation biosensor will be used. i) GAPL sensors are used to monitor the activation of heterotrimeric G proteins at the plasma membrane upon receptor stimulation. Specifically, these multi-molecular BRET sensors detect the plasma membrane recruitment of proteins that interact with active Gα subunits in a G protein family selective manner. G protein activation following receptor stimulation generally results in an increase in the BRET signal. ii) Multimolecular β-arrestin membrane recruitment biosensors enable real-time spatiotemporal monitoring of β-arrestin1 and β-arrestin2 following GPCR activation. Specifically, these β-arrestin sensors were designed to detect protein recruitment to the plasma membrane (β-arrestin PM) by localization to a compartment that results in an increase in the BRET signal.
[0167] c) Cell culture conditions HEK293 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) (Wisent; catalog no. 319-030-CL: without sodium pyruvate, with 4.5 g / L glucose, without L-glutamine) supplemented with 1% penicillin-streptomycin (Wisent; catalog no. 450-201-EL) and 2 or 10% fetal bovine serum (Wisent, catalog no. 090150).
[0168] d) Transfection and cell seeding HEK293 cells were transfected with hCB1 or hCB1b and one of the bioSensAll® assays listed above. For each transfection condition: - the total amount of transfected DNA was kept constant at 1 μg per mL of cell culture transfected, and whenever necessary, salmon sperm DNA (Invitrogen, Cat. No. 15632011) was used as "carrier" DNA to supplement the plasmid DNA (i.e. biosensor and receptor); -PEI (polyethyleneimine 25 kDa linear, PolyScience, Cat. No. 23966) to DNA ratio (ug:ug) was fixed at 3:1.
[0169] Transfection was performed as follows: -DNA and PEI were first diluted separately in 150 mM NaCl, the volume of diluent in each tube corresponding to 5% of the cell culture volume to be transfected. -Once the DNA and PEI were diluted, the PEI-containing solution was added to the DNA solution and the DNA / PEI mixture was immediately vortexed for 5 seconds. -The DNA / PEI mixture was incubated at room temperature for at least 20 minutes to allow the formation of DNA / PEI complexes. During the incubation, the HEK293 cells were detached, counted and resuspended in culture medium (composition specified above). At the end of the incubation period, the DNA / PEI mixture was added to the cells. - The cells were finally distributed in 96-well plates (White Opaque 96-well / microplates, Greiner, Cat. No. 655083 or CulturPlate-96, White Opaque 96-well microplates, PerkinElmer, Cat. No. 6005688) at a density of 30,000 cells per well.
[0170] e) BRET Assay Approximately 48 hours after transfection: Using a -450-Select TS Biotek plate washer, the culture medium was aspirated and replaced with 100 μl per well of Hank's Balanced Salt Solution Buffer (HBSS) (Wisent, Cat. No. 319-067CL: no red phenol; with sodium bicarbonate, with calcium and magnesium, with HEPES). This process was performed twice in total (i.e., two washes). -After a washing step, increasing doses (12) of test compound (ranging from 0 to 600 nM) were injected into the wells using an HP D300 digital dispenser (Tecan). After 3–5 min, the EC75 of CP-55,940 (0.1 nM for the GAPL-Gi2 assay and 100 nM for the β-arrestin PM translocation biosensor (+GRK2)) was added to columns 2–12 of each 96-well plate. Eight wells in column 1 of each plate were consistently reserved for controls (i.e., three untreated wells, two wells injected with the EC75 of CP-55,940, and three wells injected with the EC100 of CP-55,940). The plates are then incubated at 37 degC and 5% CO in a humidified atmosphere. 2 The mixture was incubated overnight (16–18 h). -The next day, the BRET experiment was performed according to the following protocol: -10 μl of 20 μM e-Coelenterazine Prolume Purple (Methoxy e-CTZ) (Nanolight, Cat. No. 369) was added to each well to give a final concentration of 2 μM. -Plates were incubated for 5 minutes at room temperature on an orbital shaker. -BRET readings were then collected on a Synergy NEO plate reader (BioTek Instruments, Inc., USA; filters: 400nm / 70nm, 515nm / 20nm) with an integration time of 0.4 seconds.
[0171] f) calculation The BRET signal was determined by calculating the ratio of the light emitted by the GFP acceptor (515 nm) to the light emitted by the luciferase-donor (400 nm). All BRET ratios were normalized with the previously established BRET values for the positive and negative controls using the following formula: The normalized BRET ratio is referred to as universal BRET (uBRET). uBRET=((BRET ratio-A) / (BA))×10000 (In the formula: A = BRET ratio obtained from negative control transfection B = BRET ratio obtained from positive control transfection
[0172] The resulting dose-response curves were fitted using a four-parameter logistic nonlinear regression model in GraphPad Prism 9.
[0173] The in vitro assay results of isomers 1 and 2 of compounds 1 to 8 prepared in Example 3 are shown in Table 1. [Table 1]
[0174] For comparative purposes, the racemic compound identified as compound 3 in JHM Lange et al., Bioorg. Med. Chem. Lett., 19 (2009), 5675-5678 was also prepared. The two isomers were separated by SFC as exemplified above, and the two isomers were tested in vitro under these conditions. The most active isomer had a Gi2 EC of approximately 5.1 nM. 50 and βarr2 EC of 28 nM 50 while the other isomers were inactive in both assays.
[0175] Numerous modifications can be made to any of the above-described embodiments without departing from the scope of the present invention. All reference, patent, or scientific literature documents mentioned in this document are incorporated herein by reference in their entirety for all purposes.
Claims
1. Compounds of Formula I 【Chemistry 1】 (In the formula, R 1 is independently selected at each occurrence from optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, halogen, cyano, nitro, hydroxy, optionally substituted alkoxy, amino, optionally substituted alkylsulfonyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted carboxyl, acyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted phosphonyl, optionally substituted phosphinyl, optionally substituted boronate, optionally substituted silyl, and imino; R 2 and R 3 are each independently selected from optionally substituted alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl groups; R 4 But -C(O)R 5 , -S(O) 2 R 5 , -C(=NR 6 ) R 5 and -C(=NR 6 ) NHC(O)R 5 is selected from R 5 is selected from optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl; R 6 is selected from hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylamino or dialkylamino, optionally substituted cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl, and optionally substituted heteroaryl, or R 6 But, R 5 and together with their adjacent atoms form an optionally substituted heterocycloalkyl or heteroaryl; X 1 But, SO 2 and C=O; a is 0, 1, 2, 3, 4, or 5; or an isomer and / or tautomer thereof, or a pharma- ceutically acceptable salt thereof.
2. The compound is a compound of formula I(a) 【Chemistry 2】 (In the formula, R 1 ~R 4 , X 1 and a is as defined in claim 1.
3. The compound is a compound of formula I(b) 【Chemistry 3】 (In the formula, R 1 ~R 4 , X 1 and a is as defined in claim 1.
4. R 4 But -C(O)R 5 , -C(=NR 6 ) R 5 or -C(=NR 6 ) NHC(O)R 5 2. The compound of claim 1,
5. R 4 But -C(=NR 6 ) NHC(O)R 5 5. The compound of claim 4,
6. R 5 is optionally substituted C 1-6 Alkyl, optionally substituted C 1-6 Alkoxy, optionally substituted C 1-6 Alkylamino, or diC 1-6 The compound of claim 1 which is alkylamino.
7. R 5 But, C 1-6 7. The compound of claim 6, which is alkyl, for example methyl.
8. R 5 2. The compound of claim 1, wherein is an optionally substituted cycloalkyl, an optionally substituted heterocycloalkyl, an optionally substituted aryl, or an optionally substituted heteroaryl.
9. R 6 The compound of claim 1 , wherein
10. R 6 But, R 5 and together with their adjacent atoms form an optionally substituted heterocycloalkyl or heteroaryl.
11. X 1 But, SO 2 2. The compound of claim 1,
12. a is 1, R 1 The compound of claim 1 , wherein is a halogen.
13. R 1 The compound of claim 12, wherein is Cl.
14. R 3 is optionally substituted C 2-6 The compound of claim 1 which is an alkyl group.
15. R 3 is optionally substituted C 6 Aryl, C 5-6 Heteroaryl, or C 5-7 The compound of claim 1 which is a heterocycloalkyl group.
16. R 3 is of the formula 【Chemistry 4】 (In the formula, R 7 is independently at each occurrence a halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 ) = NR 10 , S.O. 2 R 9 , S.O. 2 N (R 8 ) 2 , N(R 10 ) C(O)R 9 , N(R 10 ) S.O. 2 R 9 , N(R 10 ) C(O)N(R 8 ) 2 , N(R 10 ) S.O. 2 N (R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 8 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 8 together with their adjacent atoms, C 4-10 forming a heterocycloalkyl group, R 9 may independently in each occurrence: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 10 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; 16. The compound of claim 15, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
17. R 3 is of the formula 【Chemistry 5】 (In the formula, X 2 , X 3 , X 4 , X 5 , and X 6 each independently represents N and CR 11 is selected from 2 , X 3 , X 4 , X 5 , and X 6 at most three of them are N, R 11 is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 ) = NR 10 , S.O. 2 R 9 , S.O. 2 N (R 8 ) 2 , N(R 10 ) C(O)R 9 , N(R 10 ) S.O. 2 R 9 , N(R 10 ) C(O)N(R 8 ) 2 , N(R 10 ) S.O. 2 N (R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 8 , R 9 , and R 10 is as defined in claim 16, 16. The compound of claim 15, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
18. R 3 is of the formula 【Chemistry 6】 (In the formula, X 7 However, N and CR 11 is selected from X 8 , X 9 , X 10 , X 11 , and X 12 each independently represents O, NR x , and C(R y ) 2 is selected from 7 , X 8 , X 9 , X 10 , X 11 , and X 12 at most two of are or contain O or N, R 11 is as defined in claim 17, R x is independently in each occurrence hydrogen, C(O)R 9 , C(O)N(R 8 ) 2 , S.O. 2 R 9 , S.O. 2 N (R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R y is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 9 , C(O)N(R 8 ) 2 , C(R 10 ) = NR 10 , S.O. 2 R 9 , S.O. 2 N (R 8 ) 2 , N(R 10 ) C(O)R 9 , N(R 10 ) S.O. 2 R 9 , N(R 10 ) C(O)N(R 8 ) 2 , N(R 10 ) S.O. 2 N (R 8 ) 2 , N(R 8 ) 2 , P(O)(R 8 ) 2 , P(O)(OR 8 ) 2 , B(OR 8 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R y together with their adjacent atoms, C 4-10 Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 8 , R 9 , and R 10 is as defined in claim 16, 16. The compound of claim 15, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
19. R 11 is a halogen (e.g., F or Cl) or a halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 18. The compound of claim 17, wherein said aryl group is aryl, aryl, or alkyl.
20. R y is at least one occurrence halogen (e.g., F or Cl) or halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 20. The compound of claim 18, wherein said aryl group is aryl, aryl, or alkyl.
21. R 11 The compound according to claim 17, wherein is a hydrogen atom.
22. R 11 Or R y 19. The compound of claim 18, wherein each occurrence of is a hydrogen atom.
23. R 2 is optionally substituted C 2-6 The compound of claim 1 which is an alkyl group.
24. R 2 is optionally substituted C 6 Aryl, C 5-6 Heteroaryl, or C 5-7 The compound of claim 1 which is a heterocycloalkyl group.
25. R 2 is of the formula 【Chemistry 7】 (In the formula, R 12 is independently at each occurrence a halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 ) = NR 15 , S.O. 2 R 14 , S.O. 2 N (R 13 ) 2 , N(R 15 ) C(O)R 14 , N(R 15 ) S.O. 2 R 14 , N(R 15 ) C(O)N(R 13 ) 2 , N(R 15 ) S.O. 2 N (R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 13 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 4-10 Heterocycloalkyl, C 6 Aryl, and C 5-10 heteroaryl, or two R 13 together with their adjacent atoms, C 4-10 forming a heterocycloalkyl group, R 14 may independently in each occurrence: C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; R 15 independently in each occurrence: H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-7 Cycloalkyl, C 6 Aryl, and C 5-6 heteroaryl; c is 0, 1, 2, 3, 4, or 5; 25. The compound of claim 24, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
26. R 2 is of the formula 【Chemistry 8】 (In the formula, X 13 , X 14 , X 15 , X 16 , and X 17 each independently represents N and CR 16 is selected from 13 , X 14 , X 15 , X 16 , and X 17 at most three of them are N, R 16 is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 ) = NR 15 , S.O. 2 R 14 , S.O. 2 N (R 13 ) 2 , N(R 15 ) C(O)R 14 , N(R 15 ) S.O. 2 R 14 , N(R 15 ) C(O)N(R 13 ) 2 , N(R 15 ) S.O. 2 N (R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R 13 , R 14 , and R 15 is as defined in claim 23, 25. The compound of claim 24, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
27. R 2 is of the formula 【Chemistry 9】 (In the formula, X 18 But N and CR 16 is selected from X 19 , X 20 , X 21 , X 22 , and X 23 each independently represents O, NR w , and C(R z ) 2 is selected from 18 , X 19 , X 20 , X 21 , X 22 , and X 23 at most two of are or contain O or N; R 16 is as defined in claim 24, R w is independently in each occurrence hydrogen, C(O)R 14 , C(O)N(R 13 ) 2 , S.O. 2 R 14 , S.O. 2 N (R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl; R z is independently in each occurrence hydrogen, halogen, OH, CN, NO 2 , C(O)R 14 , C(O)N(R 13 ) 2 , C(R 15 ) = NR 15 , S.O. 2 R 14 , S.O. 2 N (R 13 ) 2 , N(R 15 ) C(O)R 14 , N(R 15 ) S.O. 2 R 14 , N(R 15 ) C(O)N(R 13 ) 2 , N(R 15 ) S.O. 2 N (R 13 ) 2 , N(R 13 ) 2 , P(O)(R 13 ) 2 , P(O)(OR 13 ) 2 , B(OR 13 ) 2 , C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, O.C. 1-6 Alkyl, C 6-10 Aryl, C 5-10 Heteroaryl, C 3-10 Cycloalkyl, and C 4-10 heterocycloalkyl, or two R z together with their adjacent atoms, C 4-10 Cycloalkyl or C 4-10 forming a heterocycloalkyl group, R 13 , R 14 , and R 15 is as defined in claim 23, 25. The compound of claim 24, wherein said alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group is optionally further substituted.
28. R 16 27. The compound of claim 26, wherein is hydrogen.
29. R 16 Or R z 28. The compound of claim 27, wherein each occurrence of is a hydrogen atom.
30. R in claim 24 16 is a halogen (e.g., F or Cl) or a halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 27. The compound of claim 26, wherein:
31. R 16 Or R z is at least one occurrence halogen (e.g., F or Cl) or halogenated C 1-6 Alkyl (e.g., fluorinated C 1-3 28. The compound of claim 27, wherein said aryl group is aryl, aryl, or alkyl.
32. The compound is 【Chemistry 10-1】 【Chemistry 10-2】 2. The compound of claim 1, selected from:
33. The compound is 【Chemistry 11】 3. The compound of claim 2, selected from:
34. The compound is 【Chemistry 12】 4. The compound of claim 3, selected from:
35. A pharmaceutical composition comprising a compound according to any one of claims 1 to 30, together with a pharma- ceutically acceptable carrier, diluent or excipient.
36. 32. The pharmaceutical composition of claim 31 for the treatment of an appetite-related disorder or one of its complications, a glucose regulation-related disorder or one of its complications, a fibrosis-related disorder or one of its complications, a metabolism-related disorder or one of its complications, a skin and hair growth and healing-related disorder, a gastrointestinal tract-related disorder, an obesity-related disorder or one of its complications, or a combination thereof.
37. 33. The pharmaceutical composition of claim 32, wherein the disorder associated with glucose regulation or one of its complications is selected from type I diabetes, type II diabetes, insulin resistance, prediabetes, pancreatic disease (by beta cell protection and / or increased insulin production), and associated nephropathy, neuropathy, and retinopathy.
38. 33. The pharmaceutical composition of claim 32, wherein the fibrosis-related disorder or one of its complications is selected from progressive fibrosis associated with interstitial lung disease, idiopathic pulmonary fibrosis (IPF), Hermansky-Pudlak syndrome pulmonary fibrosis (HPS-PF), cirrhosis and other liver fibrotic disorders (such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, primary biliary cholangitis), fibrotic kidney disease, skin fibrotic disorders (such as scleroderma, and chronic kidney disease).
39. 33. The pharmaceutical composition of claim 32, wherein one of the obesity-related disorders or complications thereof is selected from sleep apnea, snoring, asthma, pulmonary hypoventilation syndrome, dementia, cardiac disease, hypertension, gallbladder disease, gastrointestinal disorders, menstrual irregularities, osteoarthritis, venous stasis ulcers, coronary artery disease, arteriosclerosis, pseudotumor cerebri, osteoarthritis, high cholesterol, and increased incidence of malignant tumors of the liver, ovary, cervix, uterus, breast, prostate, or gallbladder.
